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ABSTRACT
Cellular behavior is controlled through multivariate interactions between various
biological molecules such as proteins and DNA. Various methods have previously
been proposed to model such interactions. However many of these methods require
large volumes of data to effectively estimate the associated unknown parameters. In
this work we explore the use of Bayesian methods to exploit the prior knowledge
about pathway information in combination with collected data in order to make
accurate and useful inferences about tissue level behavior. These predictions would
in turn help in the discovery of better therapeutic strategies such as the development
of better combination therapies involving kinase inhibiting drugs. Various problems
of modeling cancerous and healthy tissues from a Bayesian perspective have been
addressed in this work. We give a short description of these problems here in this
section.
An important problem in the study of cancer is the understanding of the hetero-
geneous nature of the cell population. The clonal evolution of the tumor cells results
in the tumors being composed of multiple sub-populations. Each sub-population
reacts differently to any given therapy. This calls for the development of novel (regu-
latory network) models, which can accommodate heterogeneity in cancerous tissues.
Here we present a new approach to model heterogeneity in cancer. We model het-
erogeneity as an ensemble of deterministic Boolean networks based on prior pathway
knowledge. We develop the model considering the use of qPCR data. By observing
gene expressions when the tissue is subjected to various stimuli, the compositional
breakup of the tissue under study can be determined. We demonstrate the viability
of this approach by using our model on synthetic data, and real world data collected
ii
from fibroblasts.
Another problem which is addressed in this work is the determination of locations
of dysregulations in a Boolean network used to model signal transduction networks.
Knowledge about which proteins/genes are dysregulated in a regulatory network,
such as in the Mitogen Activated Protein Kinase (MAPK) Network, can be used not
only to decide upon which therapy to use for a particular case of cancer, but also
help in discovering effective targets for new drugs. The posterior inference problem
is solved using a version of the message passing algorithm. We have done simulation
experiments on synthetic data to verify the efficacy of the algorithm as compared
to the results from the much more computationally intensive Markov Chain Monte-
Carlo methods. We also applied the model to analyze data collected from fibroblasts,
thereby demonstrating how this model can be used on real world data.
Another important issue in Bayesian computation is that the processing of the
collected data must be done as efficiently as possible in terms of computational speed
and memory requirements. The use of Markov Chain Monte Carlo methods is time
consuming and hence other methods need to be used for the analysis. The use of
conjugate exponential models is investigated in the modeling of the heterogeneity
of cancerous tissues where variational methods could be used in a straightforward
manner. Variational algorithms, which allow for the fast computations of posterior
probability distributions of variables of interest, have been used in the inference of
the compositional breakup of the heterogeneous tissue under study. The efficacy of
these methods has been demonstrated by comparing them with other methods such
as Markov chain Monte Carlo and Expectation maximization.
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NOMENCLATURE
ATP Adenosine triphosphate
RNA Ribonucleic acid
mRNA Messenger RNA
MAPK Mitogen activated protein kinase
qPCR Quantitative real-time polymerase chain reaction
MCMC Markov chain monte carlo
MH Metropolis-Hastings
FBS Fetal bovine serum
ARACNE Algorithm for the reconstruction of accurate cellular networks
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1. INTRODUCTION ∗
1.1 Background
Bayesian methods are getting more and more popular in the statistics and ma-
chine learning community as the community is finding more and more use of this
approach to solve various problems in science and engineering. In this work we have
used Bayesian methods in conjunction with other methods (such as Boolean algebra)
in the modeling of cancerous tissues. Such modeling of cancerous tissues will help
in the discovery of better therapeutic strategies such as the development of better
combination therapies involving kinase inhibiting drugs. Various problems of model-
ing cancerous and healthy tissues from a Bayesian perspective have been addressed
in this work. This thesis has three primary sections. A short introduction for the
following sections is given below.
1.2 Organization
In section 2, we deal with the modeling of the heterogeneity of cancer tissues.
We have modeled the heterogeneity in cancerous tissues as a collection of Boolean
networks. Prior knowledge about locations of various common mutations occur-
ring in cancer tissues can be encoded as stuck-at faults in the Boolean networks.
By observing gene expressions when the tissue is subjected to various stimuli, the
compositional breakup of the tissue under study can be determined. A multilevel
∗Parts of this section are reprinted with permission from “A Model for Cancer Tissue Heterogene-
ity” by A. K. Mohanty, A. Datta, and V. Venkatraj, 2013. IEEE Transactions on Biomedical
Engineering, volume 61, no. 3, pages 966 - 974, c© 2013 IEEE. doi:10.1109/TBME.2013.2294469,
and “Using the message passing algorithm on discrete data to detect faults in boolean regu-
latory networks” by A. K. Mohanty, A. Datta, and V. Venkatraj, 2014. BMC Algorithms for
Molecular Biology, volume 9, no. 20, 12 pages. doi:10.1186/s13015-014-0020-6, and “A Conju-
gate Exponential Model for Cancer Tissue Heterogeneity” by A. K. Mohanty, A. Datta, and V.
Venkatraj, 2015. IEEE Journal of Biomedical and Health Informatics, preprint, c© 2015 IEEE.
doi:10.1109/JBHI.2015.2410279.
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hierarchical model was used to account for the stochasticity in the observed data
as well as the variations among the various gene expressions. We demonstrate the
viability of this approach by using our model on synthetic data, and real world data
collected from fibroblasts.
Section 3 deals with the Bayesian estimation of possible locations of dysregula-
tions in a given Boolean network provided we have certain observed data from the
tissue under study. If we have a Boolean network used to model a signal transduction
network such as the Mitogen Activated Protein Kinase (MAPK) Network, estimat-
ing these possible locations of dysregulations in the network can prove to be useful
in not only deciding which therapy to use for a particular case of cancer, but also
help in discovering effective targets for new drugs. The posterior inference problem
is solved using a version of the message passing algorithm. We have done simulation
experiments on synthetic data to verify the efficacy of the algorithm as compared
to the results from the much more computationally intensive Markov Chain Monte-
Carlo methods. We also applied the model to analyze data collected from fibroblasts,
thereby demonstrating how this model can be used on real world data.
In section 4, we have investigated the use of variational Bayesian methods in
the computation of posterior marginal distributions of the unobserved variables in
a probability model and applied these methods to the modeling of heterogeneity
of cancer tissues. The use of conjugate exponential models is investigated in the
modeling of the heterogeneity of cancerous tissues where variational methods could
be used in a straightforward manner. Variational algorithms, which allow for the fast
computations of posterior probability distributions of variables of interest, have been
used in the inference of the compositional breakup of the heterogeneous tissue under
study. The efficacy of these methods has been demonstrated by comparing them with
other methods such as Markov chain Monte Carlo and Expectation maximization.
2
2. A BAYESIAN MODEL FOR CANCER TISSUE HETEROGENEITY ∗
2.1 Introduction
Cancer progression can be modeled as evolution among cells which become neo-
plastic due to the accumulation of mutations which give them a proliferative ad-
vantage over their normal neighbours [27]. Although there is wide spread consensus
that most macroscopic tumors have a unicellular origin as described in [27, 37], step-
wise accumulation of mutations as described in [27] causes the appearance of variant
sublines which makes the neoplastic cell population a heterogeneous one. The het-
erogeneity of cancer cell populations raises certain issues in the treatment strategy
to be followed because a certain treatment which may be effective on a certain sub-
population of the neoplastic cells but not on the others may show good results on
a particular patient, but not on another patient where the sensitive neoplastic cell
subpopulation is not a major fraction of the entire cancerous cell population. Hence
estimating the proportion wise breakup of the cell subpopulations in a cancer for any
given patient is a problem which needs to be addressed. Once the dominant sub-
populations have been identified, the appropriate decisions regarding therapy can be
taken such as which subpopulation to target and how much of therapy should be
administered to the patient. Proponents of the cancer stem cell theory [30, 1] say
that the growth and progression of many cancers are driven by small subpopulations
of cancer stem cells and that therapies should be designed to target these stem cell
subpopulations. The second popular theory is that most of the cells in the tumor
are contributive to tumor maintenance [36, 5]. Such a view would imply that ther-
∗Parts of this section are reprinted with permission from “A Model for Cancer Tissue Heterogene-
ity” by A. K. Mohanty, A. Datta, and V. Venkatraj, 2013. IEEE Transactions on Biomedical
Engineering, volume 61, no. 3, pages 966 - 974, c© 2013 IEEE. doi:10.1109/TBME.2013.2294469.
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apies should be aimed to target all the major subpopulations in the cancer tissue.
Whichever model may be closer to the true state of affairs, a mathematical model
which incorporates heterogeneity in the cancer tissue is a vital tool in the treatment
of a complex disease such as cancer.
2.2 Model description
Cellular behavior is controlled through multivariate interactions between various
biological molecules such as proteins and DNA [37, 9]. Various methods have been
proposed to model such interactions. These include differential equations [4], de-
terministic and probabilistic Boolean networks [34, 9], and Bayesian and dynamic
Bayesian networks [11, 42]. For methods such as the probabilistic Boolean networks,
the network parameters are very difficult to learn from real world data simply due to
the huge search space for the parameters. The REVEAL algorithm [21] is a general
method to learn deterministic Boolean networks from time domain data. However
time domain data is difficult to collect. In addition, a lot of the previous methods
rely on the discretization of real world observations such as gene expression levels,
which results in the loss of valuable information. The ARACNE method [23] is a
way to use continuous valued observations to determine regulatory interactions.
In the biological literature, there is a wealth of information regarding the marginal
regulatory interactions, usually referred to as pathway knowledge, which has been
collected by biologists over a long period of time. Unfortunately most genetic regu-
latory network modeling methodologies tend to ignore this information. Using this
information would result in methodologies which describe cellular behavior more ac-
curately. A method to use such prior pathway knowledge while designing networks
was presented in [19]. Here Boolean networks, which are extensively used in digital
logic design, were used to model signal transduction networks. Boolean networks,
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which involve discrete variables, are a good choice to model protein-protein inter-
action networks since such reactions involve proteins changing from one state to
another, usually by the addition or removal of phosphate groups, and are generally
accompanied by ATP hydrolysis which pushes the reactions to completion. When
such a signal transduction network contains transcription factors, then the Boolean
model can be used to model the behavior of the genes whose mRNA are transcribed
by these transcription factors. This is where we cross over to the domain of contin-
uous variables. The information obtained by observing these gene expressions can
be used to find out the relative effect of various sub-populations in the tumor tissue
on the observables. This inferred relative effect can be interpreted as the combined
effect of the proportion wise breakup of the tumor cell subpopulations as well as
other random factors.
In [18] the authors present a Boolean model of the Mitogen Activated Protein
Kinase (MAPK) signal transduction network, as reproduced in Fig. 2.1 and represent
cancer as a stuck-at fault in the network. Such a treatment reduces the problem of
the selection of kinase inhibitors for combination therapy to a simple case where the
kinase inhibitors can be selected based on their effect on the variables of interest (the
ones which are responsible for cell proliferation or apoptosis). Analysis in [18] has
been done considering only single stuck at faults at a time which can be extended to
the scenario of multiple faults. However, in either case, this approach assumes that
the entire cancerous tissue can be modeled by a single faulty network. However, in
reality, each faulty network models only one faulty cell type, that is models only one
of the subpopulations. To model the entire cancer population, we need an ensemble
of networks where the number of networks required is equal to the number of major
subpopulations in the cancer tissue. This ensemble has to be deduced from expert
knowledge. In our model, the subpopulations or networks in the ensemble exert their
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effect on the observables in a weighted average fashion. Our objective is to find out
the extent to which each network influences the behaviour of the tissue by observing
the behaviour of the outputs, which is determined by the set of parameters in the
model.
A survey of the existing literature can give us prior knowledge about the most
likely points in a network where a stuck-at fault may occur. For instance, in 30% of
human breast cancers we see an over expression of the ERBB2 gene [37]. This may
cause ligand independent firing translating to a stuck-at one fault in the Boolean
network. A stuck-at one fault at ERBB2 means that the variable corresponding to
ERBB2 in the Boolean network shown in Fig. 2.1 is always upregulated regardless
of the activity status of the proteins upstream of it. Similarly 90% of pancreatic
cancer cases have a mutated Ras gene which causes it to lose its gtpase activity [37].
In other words, we have a stuck-at one fault associated with the Ras gene. Thus
based on information such as the origin of the cancer tissue and prior knowledge of
the most likely locations where faults can take place, we can reduce the number of
networks in our ensemble.
2.2.1 A simple example
Let us consider a hypothetical cancer where we have narrowed down the number
of major subpopulations to three. Let the first subpopulation be modeled by a
Boolean network with a stuck-at one fault at ERK1/2, let the second subpopulation
have two stuck-at-one faults at ERBB2/3 and Raf, and let the final subpopulation
have a stuck-at-zero fault at PTEN. The different fault locations corresponding to the
different subpopulations are shown as purple squares in the single Boolean network
in Figure 2.1. Suppose we expose the cell culture to the drug U0126. This is a
kinase inhibitor which targets MEK1 as shown in Figure 2.1. (All the drugs used in
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this example are kinase inhibitors whose molecular targets are shown in Figure 2.1.)
Let us also assume that the serum, as typically used in tissue cultures, has EGF,
HBEGF, IGF, and NRG1 in it. If we observe the behavior of the transcription
factor SP1 (shown at the bottom of the Boolean network in Figure 2.1 with green
arrows), the first network predicts no change in the behavior of SP1 while in the
second and third networks, SP1 will be downregulated. One way to observe the
activity of SP1 is to measure the expression of a gene activated by the SP1 response
element, for instance cMYC. In the second experiment if we expose the cell culture
to a combination of AG1024 and Lapatinib, then SP1 will be upregulated in the first
and second subpopulations but downregulated in the third subpopulation.
In the control experiment with no drug exposure, it is clear that all the sub-
populations will have their SP1 transcription factors upregulated. The usual prac-
tice followed to calculate the normalized gene expression ratio is by the delta-delta
method [22]. This involves normalizing with respect to a housekeeping gene such
as GAPDH (Glyceraldehyde-3-Phosphate Dehydrogenase) followed by normalization
with respect to the control experiment. The normalized gene expression ratio is the
variable that we are interested in following.
A simple and realistic approach for modeling the normalized gene expression ratio
utilizes the ratio of two normally distributed random variables, each with its standard
deviation being directly proportional to its mean. The constant of proportionality is
called the coefficient of variation, which is assumed to be constant for all the normally
distributed random variables. A biological justification for this assumption of con-
stant coefficient of variation has been provided in [7] where the gene expressions were
measured using microarrays, while the observation of this phenomenon is reported in
[6]. In this paper, our results will be developed specific to the above example where
the observed variables are normalized gene expression ratios. However, the results
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could be extended to the analysis of other observables where the relative effect of
the various subpopulations on their behaviour is to be determined. This would re-
quire the use of models other than the ratio of two normal random variables, such as
the gamma distribution, the log-normal distribution, or any other model which best
fits the data. Though other models can be used, this model has certain advantages
when it comes to determining the unknown parameters from collected data as we
will demonstrate in the later sections.
Let us assume that we are observing the expression of a reporter gene of SP1,
say cMYC. Let the effect of the 3 subpopulations on the normalized gene expression
ratio of cMYC be in the ratio of αcMY C,1 : αcMY C,2 : αcMY C,3. We will call these
the relative ratio parameters of cMYC which represent the extent to which each
subpopulation manifests its effect on an observable (cMYC in this case). Each term
in the ratio represents the net effect of a subpopulation which includes various factors
such as the cell population and the concentration of the mRNA level in the cells.
Thus the normalized gene expression ratio of cMYC for the first experiment, where
the cell culture is exposed to U0126, is a random variable, which in turn is the
ratio of two normally distributed random variables. The one in the numerator has a
mean directly proportional to αcMY C,1 and standard deviation directly proportional
to αcMY C,1×c (where c is the coefficient of variation which is considered constant for
all genes). This is because the addition of U0126 shuts down the activity of the SP1
transcription factor in the other two subpopulations. The one in the denominator has
a mean directly proportional to αcMY C,1 +αcMY C,2 +αcMY C,3 and standard deviation
directly proportional to (αcMY C,1+αcMY C,2+αcMY C,3)×c since the control experiment
has no drugs added and therefore, the activity of SP1 is not suppressed in any
of the subpopulations. For the second experiment, following the same logic, the
normalized gene expression ratio of cMYC is a ratio of two normally distributed
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random variables. The random variable in the numerator has a mean of αcMY C,1 +
αcMY C,2 and a standard deviation of (αcMY C,1+αcMY C,2)×c while the random variable
for the denominator is the same as that for the first case.
For an intuitive understanding let us consider that the data points are generated
by a model where the coefficient of variation is 0. In that case we will simply get the
following two equations from the two experiments as shown below. If rcMY C,1 and
rcMY C,2 denote the two measured normalized gene expression ratios of cMYC from
the two experiments, we have:
αcMY C,1
αcMY C,1 + αcMY C,2 + αcMY C,3
= rcMY C,1 (2.1)
αcMY C,1 + αcMY C,2
αcMY C,1 + αcMY C,2 + αcMY C,3
= rcMY C,2. (2.2)
Since αcMY C,1 : αcMY C,2 : αcMY C,3 is a ratio, we can have the terms of the ratio
sum to 1 to get another equation.
αcMY C,1 + αcMY C,2 + αcMY C,3 = 1 (2.3)
Equations (2.1), (2.2) and (2.3) will let us calculate the relative ratio parameters
assuming the data points are drawn from a model with coefficient of variation c equal
to 0.
However, in biological experiments a large sample size is hard to come by and
sometimes we cannot afford to do a sufficient number of experiments to generate
enough information just by observing a single observable (cMYC in our example
above). For instance, if instead of the two experiments (excluding the control exper-
iment) for the case described above, we do one experiment where we expose the cell
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culture to a combination of the two drugs LY294002 and U0126, then from the faulty
networks ensemble, it is apparent that the transcription factor FOS-JUN (also known
as activator protein 1 or AP1) will be upregulated in the first and third subpopula-
tions while it will be downregulated in the second one. Looking at SP1, it will be
upregulated in the first subpopulation while it will be downregulated in the second
and third subpopulations. Let us assume that we are observing a reporter gene of
FOS-JUN. If we consider the case where c is 0 and use the same method as shown in
equations (2.1) through (2.3), we will need to use the observed values of two different
variables (a reporter gene of SP1 and a reporter gene of FOS-JUN) to estimate the
relative influence of the subpopulations on the observables. However this method
rests on the assumption that the relative effects of the different subpopulations is
the same for all the observables, which in this example are the genes transcribed by
FOS-JUN and SP1. This is a strong assumption since as mentioned earlier, the ob-
served variables are affected not only by the proportions of the subpopulations, but
also by individual random effects arising from many possible factors which make the
assumption of equal relative ratio parameters unrealistic. However the data coming
from different observables should not be ignored since all the observable data points
contain information about the proportion wise breakup of the subpopulations. This
calls for a model which utilizes all the information coming from various sources.
Even though for each individual observable variable, the proportion wise breakup
of the subpopulations is a small factor affecting its behavior, this factor affects all
the observed variables. Thus taking information from all the observed variables will
allow us to determine the proportion wise breakup among the subpopulations with
better accuracy.
One such model is the multilevel hierarchical model. In this model, the relative
ratio parameters vector αi = ( αi,1 αi,2 αi,3 )
T for each observable variable i (the genes
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transcribed by SP1 and AP1 in our examples) are drawn from a governing Dirichlet
distribution having a parameter vector which needs to be estimated from the data
points. Hence the relative ratio parameters for each observable variable i sum up to 1
and are all non negative. The parameter vector of the governing Dirichlet distribution
is representative of the average of the information from all observed variables.
2.3 A hierarchical model for heterogeneous cancer tissue
Multilevel Hierarchical models are important new tools which are becoming in-
creasingly popular in modern quantitative research. These models are useful in cases
where the data is organized as a hierarchy of nested populations. In our case such
a model is applicable since according to our requirement, the relative ratio param-
eters vector for gene i, αi = ( αi,1 αi,2 αi,3 )
T determine the distribution of the gene
expression ratio of the gene i and αi will be a different vector for each gene. For the
purpose of presentation, the coefficient of variation is not made to have a hierarchical
structure and the same value is assumed for all the observable variables, although it
is possible to develop a hierarchical structure for the coefficient of variation allowing
it to vary from gene to gene. A lot of literature is available on multilevel hierarchical
models [12, 13, 16]. So we will not go into an in-depth discussion about a general Hi-
erarchical model. Instead, in this section, we will only describe the details pertaining
to our model.
Figure 2.2 shows the conditional dependencies of the model. All the observations
for each observable variable have a probability distribution which depends on the
“relative ratio parameters” for that variable. These relative ratio parameters are
drawn from an underlying Dirichlet distribution, the parameter vector K of which
is to be estimated. A Dirichlet distribution generates vectors with non negative
values whose elements add up to 1. With the appropriate parameter vector K, the
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distribution can be made to take a variety of shapes and center around any mode
(peak value of the probability distribution). This mode can be interpreted as the
average effect of the subpopulations on the observables. The larger the values of
the elements of the parameter vector K, the “sharper” the Dirichlet distribution is
around the mode.
Another big advantage of a hierarchical model is that it allows for the sharing of
information across observables. Consider the experiment discussed in the previous
section where the hypothetical tissue was exposed to LY294002 and U0126. Looking
at SP1 and FOS-JUN separately, there is not enough information to infer the rela-
tive ratio parameters for these two observables, but combining the data from these
two observables allows us to determine the parameters of the underlying Dirichlet
distribution. This will be demonstrated using synthetic data derived from the model
of the MAPK signal transduction network in a simulation example and applied to
real data derived from experiments on fibroblasts.
The probability distribution of the normalized gene expression ratio for the jth
data point collected from an experiment involving the measurement of the ith gene
is dependent on the relative ratio parameters vector αi , the coefficient of variation
c, and the “expression profile” di,j. The expression profile is simply a vector whose
length is equal to the number of subpopulations in our ensemble. An element of
this vector di,j is 1 if the contribution to the j
th data point collected from an ex-
periment involving the ith gene is expected to be upregulated in the corresponding
subpopulation, 0 otherwise. This will change from one experiment to the next for
the same gene depending upon the behavior of the Boolean networks in the ensem-
ble. For example the expression profile for the gene transcribed by SP1 in the first
example in the previous section is ( 1 0 0 )T for the case where exposure to U0126
has occurred, and ( 1 1 0 )T for the case where exposure to AG1024 and Lapatinib
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has occurred. We make the reasonable assumption that the expression profile for
each observable variable is known for each experiment since it is dependent on the
deterministic behavior of the Boolean networks in the ensemble. As explained in the
previous section, the normalized gene expression ratio is a ratio of two normally dis-
tributed random variables. We will derive the probability density function (pdf) of
the ratio of two normally distributed random variables below. Consider two normal
random variables T1 and T2 with mean and standard deviations µ1 and c × µ1 and
µ2 and c× µ2 respectively. Define
R :=
T1
T2
(2.4)
and define
X := T2 (2.5)
Following the standard procedure for computing the joint density of functions of two
random variables, the Jacobian comes out to be
J =
∣∣∣∣∣∣∣
 X R
0 1

∣∣∣∣∣∣∣ = |X| (2.6)
Since X = T2 has very thin tails in the negative region, we get
J ≈ X (2.7)
Thus we have
PR,X(r, x) = PT1(t1)× PT2(t2)× J (2.8)
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or
PR,X(r, x) ≈ 1
2piµ1µ2c2
× exp
(
− 1
2c2µ21
(rx− µ1)2 − 1
2c2µ22
(x− µ2)2
)
x (2.9)
Define m = µ1
µ2
. Since we have PR(r) =
∫
PR,X(r, x)dx, integrating the joint
density over all x, we obtain
PR(r) =
m(r +m)√
2pic(r2 +m2)
3
2
exp
(
− 1
2c2
(r −m)2
(r2 +m2)
)
(2.10)
We note that the expression in equation 2.10 above agrees with the ratio distri-
bution derived in [7].
Define mi,j = d
T
i,jαi. Thus the conditional probability distribution of the nor-
malized gene expression ratio of the ith gene in the jth experiment comes out to
be
P (ri,j/αi, di,j, c) =
mi,j(ri,j +mi,j)√
2pic(r2i,j +m
2
i,j)
3
2
× exp
(
− 1
2c2
(ri,j −mi,j)2
(r2i,j +m
2
i,j)
)
(2.11)
Let N be the number of networks in the ensemble. For our examples we have
N = 3 since we have chosen to include 3 networks in the ensemble. However, it is
not a hard and fast rule to include exactly three networks in the ensemble since the
number of subgroups can be more or less than three. The probability distribution of
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the relative ratio parameters vector αi of the i
th gene is given by
P (αi/K) =
∏N
q=1 α
Kq−1
i,q
Beta(K)
(2.12)
where Beta(K) is the beta function defined as
Beta(K) =
∏N
q=1 Γ(Kq)
Γ
(∑N
q=1Kq
) (2.13)
Here Γ represents the Gamma function. Let ni be the number of data points
of the ith gene from all experiments combined and let V be the total number of
observables (genes). Let r denote the set of all the data points ri,j taken together.
Let d denote the set of all di,j taken together. Then considering the parameters of
interest K and c, we get the likelihood function of the data points to be
P (r/K, c, d) =
V∏
i=1
∫ ni∏
j=1
P (ri,j/αi, di,j, c)P (αi/K)dαi (2.14)
This needs to be maximized over K and c in order to obtain the maximum
likelihood estimate of K and c. The integrations can be difficult or impossible to
perform analytically. So we will resort to Markov Chain Simulation to estimate the
posterior probability distribution of the elements in the parameter vector K.
2.3.1 Estimating parameter values from observed data
Once the ensemble of networks has been chosen from biological knowledge, ex-
perimental data about gene behavior in response to kinase inhibitor drugs can be
used to estimate the parameters of the model. We will use the Metropolis-Hastings
(M-H) algorithm to generate samples from the posterior distributions of the unknown
parameters, which are the parameter vectors K, all the αi’s and the coefficient of
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variation c, conditional on all the data r. The M-H algorithm generates a Markov
Chain in the unknown parameter space whose stationary distribution is the required
posterior distribution of the unknown parameters. Letting this Markov Chain run
to stationarity and drawing samples from the Markov chain is equivalent to drawing
samples of the unknown parameters from their posterior distribution. There is a lot
of available general literature on this algorithm [12, 13, 16] and so we will simply
focus on the specifics for our case.
The usual Bayesian Method requires us to define priors over the parameters K
and c. For c, we choose the prior such that the reciprocal of the square of c is gamma
distributed with a shape parameter of v0
2
and an inverse scale parameter of
v0c20
2
.
1
c2
∼ Γ
(
v0
2
,
v0c
2
0
2
)
(2.15)
Here Γ represents the Gamma distribution and not the Gamma function.
For K we choose a proper prior where all the elements of K are independently
identically exponentially distributed. The means for these exponential distributions
can all be made equal and arbitrarily large so that the prior is almost flat as compared
to the posterior. Choosing proper prior distributions ensures that the posterior is
also proper.
To run the M-H algorithm, we need the full conditionals of the unknown variables.
Define α−i as the set {α1, α2, ..., αi−1, αi+1, ...αV }. Then the full conditional of αi is
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as follows
P (αi/K, c, r, α−i, d) ∝
ni∏
j=1
P (ri,j/αi, di,j, c)P (αi/K)
∝
ni∏
j=1
(
mi,j(ri,j +mi,j)
(r2i,j +m
2
i,j)
3
2
exp
(
− 1
2c2
(ri,j −mi,j)2
(r2i,j +m
2
i,j)
))
×
N∏
q=1
α
Kq−1
i,q (2.16)
Define α as the set of all the relative ratio parameters vectors αi’s. Let P (K) be the
prior over K. Then the full conditional of K is as follows
P (K/α, c, r, d) ∝ P (K)×
V∏
i=1
P (αi/K)
∝ P (K)× 1
(Beta(K))V
N∏
q=1
(
V∏
i=1
αi,q
)Kq−1
(2.17)
The full conditional of c is such that
1
c2
∼ Γ
((
v0 +
∑V
i=1 ni
)
2
, (
v0c
2
0 +
∑
i,j
(ri,j−mi,j)2
(r2i,j+m
2
i,j)
)
2
)
(2.18)
The parameters are sampled from their full conditionals one after the other and
after each cycle the newly generated values are stored. c can be generated from
its full conditional simply by taking a sample from the standard gamma distribution
with the above parameters as shown in equation 2.18 and taking the reciprocal of the
square root of the sample. This convenient step is possible due to the specific form
of P (ri,j/αi, di,j, c) which results from the ratio of two normally distributed random
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variables. But K and the αi’s need to be sampled from non standard distributions.
We use random walk proposal distributions to generate new values of K and αi’s
from their previous values.
New values K∗ are sampled from their proposal distributions in the following
manner. For the qth element K∗q of K
∗, do the following
• Sample t from uniform(Kq − UK ,Kq + UK), where Kq is the qth element of K.
• If t < 0, then set K∗q = −t, else set K∗q = t.
UK is a tuning parameter which can be adjusted to improve the behavior of the
Markov Chain. Using the method as described above makes the proposal distribution
symmetric [16]. The acceptance ratio for K is calculated as
RK =
P (K∗/α, c, r, d)
P (K/α, c, r, d)
(2.19)
and K is updated to K∗ with a probability of min(RK , 1).
New values α∗i are generated from a Dirichlet proposal distribution with param-
eter value vector given by αi
Uαi
. Uαi is a tuning parameter. Define D(x/y) to be the
probability distribution of x which is Dirichlet distributed with parameter y. Since
the proposal distributions used for the αi’s are not symmetric, the acceptance ratio
is calculated as
Rαi =
P (α∗i /K, c, r, α−i, d)D(αi/
α∗i
Uαi
)
P (αi/K, c, r, α−i, d)D(α∗i /
αi
Uαi
)
(2.20)
αi is updated to α
∗
i with a probability of min(Rαi , 1).
The series of steps described above results in a Markov Chain whose stationary
distribution is the same as the posterior distribution of the unknown parameters. Let-
ting this Markov Chain run to stationarity and drawing samples from the Markov
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chain is equivalent to drawing samples of the unknown parameters from their poste-
rior distribution.
Once the draws from the posterior distribution of the unknown parameters have
been obtained, we can obtain the posterior mean, the values with the maximum pos-
terior distribution value (the modes) and the confidence intervals of the parameters
from the kernel density estimate. Such estimates of the parameter vector K can then
be used to determine the proportion wise breakup of the subpopulations correspond-
ing to the networks included in the ensemble. Such methods will be demonstrated
in the coming subsections.
2.3.2 Experiments with synthetic data
To demonstrate the working of the algorithm, we ran simulations of the algo-
rithm on synthetic data. We generated synthetic data from the example described
previously which was derived from the MAPK signal transduction network, which is
a well understood network. Three networks with the “stuck-at” faults as described
in the previous example were taken in the ensemble. One reporter gene for each of
the 4 transcription factors was considered as an observable. Thus we have 4 observ-
ables with 4 different “relative ratio parameter vectors”. K was fixed to be ( 10 6 3 )T .
This corresponds to a Dirichlet distribution with a mode of ( 0.5625 0.3125 0.1250 )T . c
was fixed to be 0.1 since typical values of the coefficient of variation were reported
in [7] to be close to 0.17. First the “relative ratio parameters” for the 4 observ-
ables were generated from the Dirichlet distribution with parameter vector K and
then held fixed for each reporter gene for the 4 transcription factors FOS-JUN, SP1,
SRF-ELK1, and SRF-ELK4. Then observations of the observables were generated
for various combinations of drugs following the model of the ratio of two normally
distributed random variables. 12 drug combinations were chosen out of the 63 pos-
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sible combinations of the 6 drugs in the model in such a way so that the “expression
profiles” for each gene cannot generate a sufficient number of equations permitting
calculation of the “relative ratio parameters” for that gene, in the event that the co-
efficient of variation c were zero. For example all observed data-points corresponding
to the reporter of FOS-JUN had their corresponding expression profiles as ( 1 0 1 )T
and all observed data-points of the rest of the observables had their corresponding
expression profiles as ( 1 0 0 )T . This is done so as to demonstrate how the sharing
of information from all the observables can be used to obtain an estimate of the
parameter vector K of the underlying Dirichlet distribution.
For the purposes of demonstrating the algorithm, the prior for the elements of
the parameter vector K were chosen to have exponential distributions with means of
1000, and the parameters for the prior of c were chosen as follows. The value v0 was
taken as 1 and c0 was taken to be 0.
The Markov Chain was run for 3000 iterations to make it reach stationarity. The
tuning parameters were adjusted to get acceptance rates of close to 30% for the
unknown parameters. The Markov chain was run for 400,000 iterations and thinned
100 times (1 in 100 samples generated was stored for each parameter). This resulted
in a maximum inefficiency factor of less than 4 among all the parameters. The reader
is referred to [12, 13, 16] for information on Markov Chain Monte Carlo diagnostics
and the inefficiency factor.
Multivariate kernel density estimation for any general N dimensional parameter
vector is made using the multivariate Gaussian kernel with a diagonal covariance
matrix, the jth element of which is given by Cj =
(
σj
n
1
N+4
)2
, where σj is the standard
deviation of the jth element of the parameter vector under consideration, n is the
number of samples drawn from the posterior distribution, and N is the number of
elements in the parameter vector (3 for K in our example). This rule of thumb is
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discussed in [33].
Figure 2.3 shows the kernel density estimate of the marginal distributions of
the elements of K along with their priors. The priors are far too spread out and
non-informative as compared to the posteriors. Hence the value of K with the
maximum posterior distribution is equivalent to the maximum likelihood estimate.
This estimate comes out to be ( 9.1367 5.1330 2.2130 )T which was estimated from the
kernel density estimate of the joint distribution of the 3 elements of the parameter
vector K using gradient ascent with non-negativity constraints. Comparing it to the
actual value of K, we can see that it is quite close. Confidence intervals can also
be calculated from the kernel density estimates, although we have not shown such
calculations here. The more the data fed to the model, the more accurate is the
estimate and the confidence intervals are narrower.
We are more interested in the posterior distribution from which the relative ratio
parameters of the observables come. That is if we know the parameter vector K,
we would like to know the distribution of the relative ratio parameters, which is
nothing but Dirichlet distributed with the parameter vector K. But since K has a
posterior distribution, we would like to know the value of
∫
P (α/K)P (K/r, d) dK,
where α = ( α1 α2 α3 )T is Dirichlet distributed with parameter vector K, and r is the
set of all observed data points. This can be obtained by sampling α from Dirichlet
distributions with parameters set as the samples drawn from the posterior of K.
Repeating this process for all the samples of K, we get the samples of α. The
posteriors of the elements of α for this example are shown in Figure 2.4. The mode
is derived from the kernel density estimate using gradient ascent subject to the
constraint that the elements of α sum to 1 along with non-negativity constraints.
The mode obtained is ( 0.5974 0.2930 0.1095 )T . Comparing it to the original mode of
( 0.5625 0.3125 0.1250 )T , we can see that it is quite close.
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2.3.3 Verification using experimental data
In order to test if the theory developed so far would work, we need to collect
data from an experiment performed on a tissue where the dominant population or
the dominant network is known. In a cancerous cell line, one cannot be sure which
network is dominant. But in a normal cell line, such as adult fibroblasts, it is fair to
assume that a network modeling a faultless MAPK signal transduction network would
be the most dominant one, no matter what networks are included in the ensemble.
Hence we performed a simple experiment on adult fibroblasts to demonstrate the
approach.
Adult fibroblasts were grown in Fibroblast Basal Medium (ATCC) in 60mm tis-
sue culture petri dishes till confluence. Following this, the cells were maintained in
Dulbecco’s modified Eagles medium-F12 (DMEM/F12) (Atlanta Biologicals), sup-
plemented with 0.2% fetal bovine serum (Atlanta Biologicals) for 4 days (All concen-
trations of the supplements used were calculated with respect to plain DMEM/F12
medium without serum). The medium was changed every day after wash with phos-
phate buffer solution (PBS). All cell cultures were incubated at 37 ◦C in a 5% CO2
incubator.
The cells were then exposed to DMEM/F12 supplemented with 0.2% FBS and
100µM Anisomycin for 30 minutes. Anisomycin is a protein synthesis inhibitor which
activates the MAPK signal transduction network and keeps it responsive to kinase
specific inhibitors [2, 10]. That is, with the addition of Anisomycin, we anticipate
the MAPK signal transduction network to respond to the addition of a drug such
as U0126. Anisomycin, being a protein synthesis inhibitor, would also cut of any
feedback path which has a translation (protein synthesis) step in it. The tissue
culture petri dishes were then grouped into 3 groups (groups 0, 1 and 2). After
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the initial 30 minutes of exposure to Anisomycin, each group was then exposed to
DMEF/F12 supplemented with 20% FBS,100µM Anisomycin, 50µM of LY294002,
and/or 10µM of U0126 as shown in table 2.1.
Group 0 is not exposed to LY294002 or U0126, which are highly specific inhibitors
of PI3 Kinase (PI3K in Figure 2.1) and MEK1 respectively. The molecular targets of
LY294002 and U0126 are shown in Figure 2.1. Genes having the SP1 and SRF-ELK
response elements in their promoters were quantified through real time PCR and
the delta-delta method [22] with GAPDH as the reference gene and group 0 as the
control.
EGR1 is measured as a reporter gene of SRF-ELK transcription factor [8]. JUN,
BIRC5, and cMYC are measured as reporters of SP1 [31, 24, 20]. Other genes
having the SP1 response element in their promoters are Decorin, IRF3 and VEGFA
[35, 40, 32, 29]. Four different alternative transcripts of Decorin were measured.
Thus we have a total of ten observables. The expression values calculated are shown
in table 2.2.
For the sake of demonstration we assumed 3 networks to be in the ensemble.
Network 1 has no mutations, i.e. no “stuck-at” faults. This network models the
normally behaving fibroblasts. Network 2 is assumed to have a “stuck-at 1” fault
at ERK1/2 and network 3 is assumed to have “stuck-at 1” faults at SRF-ELK1
and SRF-ELK4. The “expression profiles” for all the genes for the experimental
conditions of groups 1 and 2 are known and depend on the behaviour of the 3
networks included in the ensemble. These are shown in table 2.2.
As described in the previous section, samples from the posterior distributions of
the unknown parameters were drawn using the Metropolis-Hastings Algorithm. The
number of samples were drawn until the effective sample size was atleast 300 for all
the parameters. The reader is referred to [16] for information on effective sample
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sizes in Markov Chain Monte Carlo analysis.∫
P (α/K)P (K/r, d) dK was estimated as described in the previous section. The
marginals of the 3 components of α are shown in Figure 2.5. The spread of the
distribution is large due to lack of enough data points. The mode is derived from
the kernel density estimate using the gradient ascent subject to the constraint that
the elements of α sum to 1 and non-negativity constraints. This mode comes out
to be ( 0.6453 0.2255 0.1292 )T . As expected, the faultless network representing normal
fibroblasts has the maximum influence on the behaviour of the observables, close to
65% . This simple experiment is a demonstration of how real world technology such
as QPCR can be used to determine the composition of a heterogeneous tissue.
2.4 Summary and comments on possible future work
In this work we addressed the important problem of heterogeneity in cancer tis-
sues and presented a model which has the ability to use prior pathway knowledge
and knowledge about likely mutations in cancers to represent a heterogeneous cancer
tissue as an ensemble of faulty Boolean networks. We demonstrated the general idea
of our approach by considering the observed variables to be genes transcribed by key
transcription factors. We modeled the gene expression ratios as ratios of normally
distributed random variables whose means were affected by the networks in the en-
semble to varying degrees. However, if some other observables are used, then the
ratio of normally distributed random variables formulation may not hold and hence
the lowest level of the hierarchical model would have to be altered. However, the
overall approach of hierarchically modeling the relative ratio parameters would re-
main the same. We also demonstrated how the Metropolis-Hastings MCMC method
can be used to estimate the relative effect that each subpopulation exerts on the
observed variables. This estimate gives us an idea about which subpopulation is the
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most dominant one among all the subpopulations in the ensemble. Such estimates,
if obtained using data from individual patients, could help customize combination
therapy design and could help improve the success rate of such cancer therapies. for
more information on this work, the reader is referred to [25].
Future work could also focus on algorithms that allow the addition of networks
other than the ones with which the algorithm starts or the deletion of networks so
as to better fit the data. The results in this paper have been developed with qPCR
data in mind. However, we do believe that similar models could be developed to
integrate data from more modern technologies such as Next Generation Sequencing
and flow cytometry combined with prior pathway knowledge in order to determine
the compositional breakup of the tissue. The details, of course, would need to be
worked out and could form the basis for future investigations. Work on speeding up
the computation of the posterior marginals has also been done and is described in
later sections of this thesis.
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Figure 2.1: A Boolean network model of the MAPK signal transduction network
with target locations of inhibitory drugs shown.
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Figure 2.2: A Bayesian network representing the conditional dependencies in our
model.
Figure 2.3: Marginal distribution of the elements of the parameter vector K.
Table 2.1: Table showing which groups were exposed to which compounds
FBS Anisomycin LY294002 U0126
Group 0 X X
Group 1 X X X
Group 2 X X X X
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Figure 2.4: Marginal distribution of the elements of α for simulation experiments.
Table 2.2: Table showing the normalized gene expression ratios, their reference se-
quence (RefSeq) numbers and their “expression profiles”
gene RefSeq group 1 group 2
exp. profiles norm. gene exp. exp. profiles norm. gene exp.
EGR1 NM 001964.2 1 1 1 0.598739352 0 1 1 0.47963206
JUN NM 002228.3 1 1 1 0.493116352 0 1 0 0.154963462
BIRC5 NM 001168.2 1 1 1 0.579867973 0 1 0 0.384218795
CMYC NM 002467.4 1 1 1 0.320856474 0 1 0 0.257028457
DNC(Decorin)
NM 133504.2 1 1 1 0.081899588 0 1 0 0.008668512
NM 133505.2 1 1 1 0.072795849 0 1 0 0.024180703
NM 133507.2 1 1 1 0.334481889 0 1 0 0.166085727
NM 133503.2 1 1 1 0.435275282 0 1 0 0.279321785
IRF3 NM 001571.5 1 1 1 0.517632462 0 1 0 0.262429171
VEGFA NM 003376.5 1 1 1 0.444421341 0 1 0 0.316439148
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Figure 2.5: Marginal distribution of the elements of α for data derived from experi-
ments on fibroblasts.
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3. USING THE MESSAGE PASSING ALGORITHM ON DISCRETE DATA TO
DETECT FAULTS IN BOOLEAN REGULATORY NETWORKS ∗
3.1 Introduction
Modeling cellular behavior is a first step towards the holistic understanding of
the multivariate interactions among various genes. One possible approach to do that
is through gene regulatory networks. These networks could also help in developing
better intervention strategies in order to shift the state of the cell or the tissue to a
more favorable one. Many different approaches have been proposed in the literature
for modeling the behavior of genetic regulatory networks. Many of these methods
have been discussed in the previous sections. These include differential equations [4],
deterministic and probabilistic Boolean networks [34, 9], and Bayesian and dynamic
Bayesian networks [11, 42]. Some of these methods rely on the assumption that the
transition probabilities are provided beforehand. Such an assumption may not be
realistic since the sheer volume of data required to effectively estimate the transition
probabilities makes it a practically difficult proposition. Some methods such as the
REVEAL algorithm [21] provide approaches to learn deterministic Boolean networks
from discretized time course data. However time course data from biological samples
itself can be difficult to come by.
One way to get around the problem of insufficient data is to use prior knowledge
about the regulatory interactions between the various biological molecules in a cell.
In the biological literature, a lot of information is available regarding the various
regulatory interactions. This information has been collected by biologists over a long
∗Parts of this section are reprinted with permission from “Using the message passing algorithm
on discrete data to detect faults in boolean regulatory networks” by A. K. Mohanty, A. Datta,
and V. Venkatraj, 2014. BMC Algorithms for Molecular Biology, volume 9, no. 20, 12 pages.
doi:10.1186/s13015-014-0020-6.
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period of time. These regulatory interactions, collectively referred to as pathway
knowledge, are generally not incorporated into the various methods of modeling
gene regulatory networks. Using this information, however, would result in models
which describe cellular behavior more accurately.
A possible approach to use such prior information has been developed in [19]. In
that reference, the authors use Boolean logic to model signal transduction networks.
In [25], the authors have used boolean models derived from prior information to
model the heterogeneity of cancerous tissues. Furthermore, in [18] Boolean logic is
used to model the Mitogen Activated Protein Kinase (MAPK) signal transduction
network and the result of that modeling is shown in Figure 2.1. Here, each connect-
ing wire corresponds to a variable which represents the state of the corresponding
protein/gene. In this model each variable is assumed to have two states, an activated
and a deactivated one. For example the state of EGFR will be upregulated or acti-
vated when the cell is exposed to EGF. The way the various variables are dependent
on each other can be modeled using standard Boolean logic functions such as AND,
OR, NOT, NAND, etc.. This is shown in Figure 2.1. In [18] the authors presented
a stuck-at fault model of the mutations which result in the neoplastic behavior of
the tissue. A stuck-at-one fault corresponds to a variable permanently being in an
activated state irrespective of the states of the variables upstream of it. Similarly
a stuck-at-zero fault would mean a variable has a permanently downregulated state
irrespective of the states of the other upstream variables. These “stuck” variables
would however affect the variables downstream of them through the Boolean Logic
gates which have these variables as inputs. To show how Boolean regulatory networks
with stuck-at faults can be used to model cancerous tissue, we give the following ex-
amples. In 30% of human breast cancers there is an over expression of the ERBB2
gene [37]. This causes ligand independent firing translating to a stuck-at-one fault
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in the Boolean network. A stuck-at one fault at ERBB2 means that the variable
corresponding to ERBB2 in the Boolean network shown in Figure 2.1 is always up-
regulated regardless of the activity status of the variables upstream of it. Similarly in
90% of the pancreatic cancer cases we see a mutated Ras gene which causes it to lose
its gtpase activity [37]. In other words, we have a stuck-at-one fault associated with
the Ras variable. Stuck-at faults could also be interpreted as points of dysregulation
in the Boolean network brought about by certain genes irrespective of the presence
of mutations.
Locating stuck-at faults in a given Boolean regulatory network could help in the
identification of key dysregulated genes that have a strong impact on the observable
variables. This in turn could be used to identify targets for new drugs. Knowledge
about the locations of the stuck-at faults along with knowledge about the targets of
the kinase inhibitory drugs can be used to come up with optimal intervention strate-
gies. A method to devise optimal intervention strategies using such Boolean regula-
tory networks with stuck-at faults is described in [18]. Accordingly, the problem we
pose is this: given data points, where each data point consists of a combination of
drugs used as the input and the activity of the observable variables as outputs, is it
possible to locate the variables where stuck-at-faults have occurred? In the following
sections we represent the problem as a statistical model with unknown parameters
which are estimated from the data points using the message passing algorithm. This
algorithm allows for rapid computation of the posterior probabilities of the parame-
ters. The estimates obtained are evaluated by comparison with the results given by
Markov Chain Monte Carlo methods.
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3.2 Model description
There are many ways to model a gene regulatory network which describes the
behavior of neoplastic tissue. The general rule is that the more the number of
unknown parameters, the more the amount of data that is required to get an effective
estimate of those parameters. Hence the modeling must be done keeping in mind
the limited amount of data available from biological experiments.
As has been pointed out before, literature survey would enable us to know the
most likely locations in the Boolean network where stuck-at faults can take place.
As stated in the previous sections, in 30% of human breast cancers there is an over
expression of the ERBB2 gene, and in 90% of the pancreatic cancer cases we see a
mutated Ras gene. These are among many examples where prior knowledge about
locations of faults is available. This knowledge would allow us to limit the search
space for faults in the network. For example we may provide a set of locations where
we want to search for faults.
One important assumption made in the modeling of mutations is that they are
random events that occur independently of each other [15, 14, 41]. We make use
of this assumption in our model by assuming that the faults occur unconditionally
independent from each other with certain unknown probabilities associated with
them. These unknown probability parameters are to be estimated from the collected
data. These estimated probabilities will indicate our confidence about where the
faults have occurred in the Boolean regulatory network.
We now explain the key ideas through a simple example. Let us assume that we
have narrowed down the set of locations where we want to search for faults to be
composed of RAF, IRS1, and RHEB as shown in Figure 2.1 (we are assuming stuck-
at-one faults). Let their probabilities of occurrences be ρ1, ρ2, and ρ3 which are to
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be determined. Define ρ = ( ρ1 ρ2 ρ3 )T as the vector of the three parameters. Three
possible locations of faults implies that there are 23 different fault combinations and
their associated networks corresponding to the binary numbers 000, 001,....,111. The
first network is one with no faults and has a probability of
P (M = 0/ρ) = (1− ρ1)(1− ρ2)(1− ρ3). (3.1)
The second network has a single stuck-at-one fault at RHEB alone, and it’s prob-
ability is given by P (M = 1/ρ) = (1 − ρ1)(1 − ρ2)ρ3. Similarly, the third network
has a single stuck-at-one fault at IRS1 alone, with a probability of P (M = 2/ρ) =
(1 − ρ1)ρ2(1 − ρ3), and so on. The variable M is the decimal equivalent of the
binary number representing the different fault combinations and could equivalently
represent the particular faulty Boolean network being considered. Since there are
three possible locations where stuck-at-faults can take place in this example, M can
take 23 = 8 different values. In our convention, we use integers from 0 to 23 − 1 to
represent the values taken by M . For example M = 6 corresponds to a network with
faults at RAF and IRS1 but not at RHEB and has a corresponding probability of
ρ1ρ2(1− ρ3).
In this example the dimension of ρ is three, but it can be any integer depending
on the size of the search space. Determining the entries of ρ allows us to determine
the most likely faulty networks. Let V be the dimension of ρ. Then it is clear that
P (M = m/ρ) has the following form:
P (M = m/ρ) =
V∏
v=1
ρRv,mv (1− ρv)1−Rv,m (3.2)
where Rv,m is either 0 or 1 and m can vary from 0 to 2
V − 1.
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Consider any one of the variables represented as arrows at the bottom of figure 2.1.
Let us represent that variable by Oj. j varies from 1 to 7 in our example based on
figure 2.1. The behavior or Oj is determined by the network and what faults are
in it. Let oi,j be an observation of that variable when the combination input is Ii.
oi,j can be either 0 or 1 since we are dealing with a boolean network here. Given
that the network M is any one of the 2V possible networks and given that the
drug combination input is Ii, the probability P (Oj = oi,j/M = m, Ii) can be either
0 or 1. It is 1 when oi,j matches the output of the j
th output variable of the mth
network for the the input drug combination Ii, and is 0 otherwise. Let us represent
P (Oj = oi,j/M = m, Ii) by Sm,i,j. The probability P (M = m/ρ) is a function of ρ
as described in equation (3.2). Therefore, by the theorem of total probability,
P (Oj = oi,j/Ii, ρ) =
2V −1∑
m=0
Sm,i,jP (M = m/ρ) (3.3)
In our example, we will proceed by assuming that the observable variables (the
Oj’s) are independent given the faulty network and the drug combinations. This
assumption can be easily relaxed for the case when the 7 observable variables rep-
resented as arrows at the bottom of figure 2.1 are observed together for each drug
combination used as the input. In this case, instead of P (Oj/M), we will be working
with P (O1, O2, ..., O7/M). This however does not affect our fundamental results and
is a simple extension of our example.
Let O represent all of the observed data for all the observable variables and I rep-
resent the entire set of the corresponding inputs. Let J be the number of observable
variables and N be the number of observations for each observable variable. Then
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we have
P (O/ρ, I) =
J∏
j=1
N∏
i=1
P (Oj = oi,j/Ii, ρ) (3.4)
which is nothing but the likelihood function. In order to handle experimental repeats,
we can have the the drug combinations Ii to be the same for more than one value of
the index i.
An estimate of ρ can be obtained from equation 3.4, either by maximum likelihood
estimation, or by calculating the posterior mean of the parameters. If the prior
distributions of all the elements of ρ are assumed to be uniformly distributed between
0 and 1, the posterior distribution of ρ is directly proportional to P (O/ρ, I). If
P (O/ρ, I) comes out to be zero for all values of ρ, then we have every reason to
question the validity of the Boolean network used to model the behavior of the
biological network, or the set of possible locations of faults. Various estimates of ρ,
such as the posterior mean or the posterior mode (the value of ρ where the posterior
distribution is maximal) can be obtained from P (O/ρ, I). Now we can algebraically
expand the right hand side of equation (3.4) to write P (O/ρ, I) as
P (O/ρ, I) =
∑
k
V∏
v=1
ρ
Q1v,k
v (1− ρv)Q2v,k (3.5)
whereQ1v,k andQ2v,k are non negative integers. Calculating P (ρ/O, I) from P (O/ρ, I)
is now trivial since it only involves calculation of a multiplicative normalization con-
stant.
P (ρ/O, I) =
P (O/ρ, I)∫
P (O/ρ, I) dρ
(3.6)
where in the denominator there is the normalization constant which turns out to be
∫
P (O/ρ, I) dρ =
∑
k
V∏
v=1
β(Q1v,k + 1, Q2v,k + 1) (3.7)
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where β(∗, ∗) is the beta function. This equation is derived by considering a uniform
prior on all the elements of ρ. The integrations can be done easily because of the form
of equation 3.5. Each variable ρv is integrated from 0 to 1. Equation 3.6 shows the
joint posterior distribution of all the unknown parameters ρ1 through ρV considered
together. In order to find the marginal distribution of any given parameter of interest,
we will need to integrate out the rest of the parameters. For example P (ρl/O, I) for
any given value of l can be found out to be
P (ρl/O, I) =
∑
k ρ
Q1l,k
l (1− ρl)Q2l,k
∏V
v=1
v 6=l
β(Q1v,k + 1, Q2v,k + 1)∑
k
∏V
v=1 β(Q1v,k + 1, Q2v,k + 1)
(3.8)
Following this the posterior means can also be calculated.
However the number of additive terms in equation 3.5 represented by the summing
variable k in general rises exponentially with the number of data points collected.
In the worst case, the left hand side of equation (3.3) will contain 2V terms. Since
the number of multiplicative terms in equation 3.4 is NJ (the number of data points
collected), upon expanding the right hand side of equation 3.4 we get 2V NJ additive
terms in equations 3.5, 3.7, and 3.8. Thus the computational cost to compute the
mean of any given ρl is O(2
V NJ). Hence the total computation cost to compute the
posterior means of all the elements of ρ (ρ1 through ρV ) is O
(
V × 2V JN). Therefore
the straightforward approach for calculating the posterior distributions of ρl’s and
their posterior means will get intractable as the amount of data collected increases.
To get around this difficulty we will use an iterative algorithm to obtain an
approximation of the marginal distributions of the elements of the parameter vector
ρ. From the marginal distribution it will be straightforward to obtain the posterior
means and confidence intervals of the individual elements of ρ.
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3.3 Factor graph representation of the model
Factor Graphs are an important tool used in various applications such as signal
processing and telecommunications. Many algorithms can be easily understood and
derived using the factor graph approach. These include Kalman Filters, the Viterbi
Algorithm, the Forward-Backward algorithm and Turbo Codes to name a few. The
approach involves first representing the probability model as a factor graph and then
applying the message passing algorithm along the edges. The reader is referred to [17]
and [39] for an in-depth coverage of factor graphs and the message passing algorithm.
Here we provide a short primer to the subjects and go into the details of only our
particular example.
3.3.1 A simple example
Consider a simple function g (x1, x2, x3) = f1 (x1, x2)× f2 (x2, x3) f3 (x3), where
xi are discrete variables. Suppose we want to calculate
∑
x1,x3
g (x1, x2, x3) for a
particular value of x2 (the marginal of x2). In addition, suppose that each xi can
take A different values. Hence the straight forward approach would require us to
sum g (x1, x2, x3) over A
2 different values. However
∑
x1,x3
g (x1, x2, x3) can also be
calculated as
∑
x1,x3
g (x1, x2, x3) =
(∑
x1
f1 (x1, x2)
)(∑
x3
f2 (x2, x3) f3 (x3)
)
(3.9)
which sums over 2A different values. For continuous variables, the summation is
replaced by integration. The optimal strategy for calculating the marginal of x2 is
straightforward to derive in this simple example. However a systematic approach
to find the optimal strategy to calculate the marginal of any variable for any given
probability function is given by the message passing algorithm which acts on the
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factor graph representation of the function.
The factorization of a function can be represented by a factor graph. A factor
graph is a bipartite graph with a variable node corresponding to each variable xi and
a factor node corresponding to each independent factor fj and has an undirected
edge connecting a variable node of xi to a factor node of fj iff xi is an argument
of fj [17, 39]. The factor graph of g (x1, x2, x3) is shown in figure 3.1. Messages
pass along the edges in both directions. Messages are functions of the variable whose
node is associated with the edge. Let µfj→xi (xi) and µxi→fj (xi) denote the messages
from fj to xi and vice versa. We simply write down the update equations below.
For an in-depth discussion on their derivation, the reader is referred to [17] and [39].
The messages are calculated as follows:
µxi→fj (xi) =
∏
h∈n(xi)\{fj}
µh→xi (xi) (3.10)
µfj→xi (xi) =
∑
∼{xi}
fj (X) ∏
y∈n(fj)\{xi}
µy→fj (y)
 (3.11)
where n (xi) and n (fj) denote the neighbors of xi and fj respectively in the
factor graph. n (xi) \{fj} represents the set of all the neighbors of xi except fj. The
definition of n (fj) \{xi} is similar. Since the factor graph is bipartite, the neighbors
of a variable node can only be factor nodes, and the neighbors of a factor node
can only be variable nodes. X denotes the set of arguments of fj.
∑
∼{xi} denotes
summation over all local variables except xi. The set of local variables will simply
be the set X, since the factor node fj is connected by undirected edges only to the
variable nodes of its arguments. The message going away from a leaf variable node is
the constant 1, while the message going away from a leaf factor node is the value of
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that local factor. Using these rules on the simple example, we have µx1→f1 (x1) = 1
and µf3→x3 (x3) = f3(x3).
The marginal distribution of a variable is simply the product of all the messages
being received by the corresponding variable node. Hence
∑
x1,x3
g(x1, x2, x3) =
µf1→x2(x2) × µf2→x2(x2) and thus equation (3.9) is derived using factor graphs and
the message passing algorithm. Calculating the rest of the messages would allow
us to calculate the marginals of x1 and x3 as well. The message passing algorithm
would terminate when messages along both directions of all the edges in the graph
have been calculated.
µf1→x2(x2) =
∑
∼{x2}
f1 (x1, x2)µx1→f1 (x1) =
∑
x1
f1 (x1, x2) (3.12)
µx3→f2(x3) =
∏
h∈n(x3)\{f2}
µh→x3(x3) = µf3→x3(x3) = f3(x3) (3.13)
µf2→x2(x2) =
∑
∼{x2}
f2 (x2, x3)µx3→f2 (x3) =
∑
x3
f2 (x2, x3) f3 (x3) (3.14)
The message passing algorithm terminates and gives exact marginals for the cases
where the factor graph has no cycles. But the most interesting applications are for
those cases where the factor graph has cycles, where the marginals are calculated by
iteratively updating the messages (for example the iterative decoding of turbo codes).
We similarly use an iterative version of the message passing algorithm in our model
to approximate the marginal posterior distribution of the unknown parameters.
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3.3.2 Using factor graphs and the message passing algorithm on the signal
transduction network model
Now, P (ρ/O, I) ∝ P (O/ρ, I) as is evident from equation (3.6), while the expres-
sion for P (O/ρ, I) is given in equation (3.4). Let Pi,j represent the multiplicative
factor P (Oj = oi,j/Ii, ρ) in equation (3.4). In a factor graph, each multiplicative fac-
tor is represented by a factor node and each element of ρ is represented by a variable
node. Hence there are NJ number of factor nodes with each corresponding to one
particular multiplicative term in equation 3.4, and there are V number of variable
nodes with each corresponding to one particular unknown parameter (one out of ρ1
through ρV ). The purpose of this algorithm is to compute the posterior marginal
distributions of the unknown parameters ρ1 through ρV , which can then be used to
compute their means and confidence intervals.
Figure 3.2 shows the factor graph of equation (3.4). As we can see the factor graph
in figure 3.2 has cycles. In a factor graph with cycles, the message passing algorithm
does not terminate and the messages are locally updated with every iteration. Every
time a new message is calculated, it replaces the old message. The iterative message
passing algorithm is as follows:
1. initialize all µρv→Pi,j (ρv) = 1
2. calculate all µPi,j→ρv (ρv) as per equation (3.11).
3. calculate all µρv→Pi,j (ρv) as per equation (3.10).
4. repeat steps 2 and 3 in that order.
Since we are dealing with continuous variables between 0 and 1, the summations are
replaced by integrations. Every time µPi,j→ρv (ρv) are computed in step 2, they come
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out to be polynomials of degree one due to the multiplicatively separable nature of
the integrands involved and that all the parameters ρv are being integrated from 0 to
1 (a rectangular integration region). Let them be represented as b0,v,i,j + b1,v,i,j × ρv.
Hence µPi,j→ρv (ρv) can be represented by a vector bv,i,j = ( b0,v,i,j b1,v,i,j )
T . Every
time µρv→Pi,j (ρv) are computed in step 3, they will be polynomials of degree NJ − 1
since they are simply the product of all incoming messages except one. Let them be
represented as
∑NJ−1
k=0 ak,v,i,jρ
k
v . Hence µρv→Pi,j (ρv) can be represented by a vector
av,i,j = ( a0,v,i,j a1,v,i,j ... aNJ−1,v,i,j )
T .
The values b0,v,i,j and b1,v,i,j can be updated in step 2 as follows.
b0,v,i,j ←
2V −1∑
m=0
Sm,i,j(1−Rv,m)×
∏
l{1...V }
l 6=v
(
NJ−1∑
k=0
ak,l,i,j
k + 2
)Rl,m
×
(
NJ−1∑
k=0
ak,l,i,j
(k + 1)(k + 2)
)1−Rl,m
(3.15)
b1,v,i,j ←
2V −1∑
m=0
Sm,i,j(2Rv,m − 1)×
∏
l{1...V }
l 6=v
(
NJ−1∑
k=0
ak,l,i,j
k + 2
)Rl,m
×
(
NJ−1∑
k=0
ak,l,i,j
(k + 1)(k + 2)
)1−Rl,m
(3.16)
The av,i,j can be updated in step 3 by performing polynomial multiplications of
the NJ−1 incoming first degree polynomials to the v′th variable node and comparing
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coefficients. That is, the following equation must be satisfied.
NJ−1∑
k=0
ak,v,i,jρ
k
v =
∏
g 6=i,h 6=j
(b0,v,g,h + b1,v,g,h × ρv) (3.17)
By comparing coefficients of either side of equation (3.17), the values of the elements
of the vector av,i,j are updated. This is also equivalent to the convolution of the
message vectors bv,g,h for g 6= i, h 6= j. At each iteration, the message vectors can be
multiplied by constants so as to prevent overflow or underflow when implementing
the algorithm on a digital computer with finite precision. In that case the final solu-
tions we get are simply the required marginal distributions scaled by some unknown
constant. If we are simply interested in the marginal distributions, then it is not
necessary to keep track of the multiplied constants. We simply need to normalize
the marginals so that their integrals from 0 to 1 give unity.
The message vectors av,i,j and bv,i,j are iteratively updated until some convergence
criteria is satisfied (for example if the Hellinger distance between the marginals of
two successive iterations is below a certain threshold). In our simulations, we saw
that as few as 2 iterations gave satisfactory results in terms of convergence. Hence
the time complexity of the algorithm is dependent on steps 2 and 3 of the algorithm.
In order to calculate µρv→Pi,j (ρv) in step 3, first calculate the polynomial Uv (ρv) =∏
g,h µPg,h→ρv (ρv) of degree NJ . Then find the quotient of the division operation
Uv (ρv) ÷ µPi,j→ρv (ρv). This gives µρv→Pi,j(ρv). Along with that, we can also cal-
culate and store the value of θv,i,j,1 =
∫ 1
0
ρvµρv→Pi,j(ρv)dρv and θv,i,j,0 =
∫ 1
0
(1 −
ρv)µρv→Pi,j(ρv)dρv which will be used in step 2. Note that θv,i,j,1 =
∑NJ−1
k=0
ak,v,i,j
k+2
and
θv,i,j,0 =
∑NJ−1
k=0
ak,v,i,j
(k+1)(k+2)
. Calculating the coefficients of Uv (ρv) is of time complex-
ity at most O ((NJ)2). This is because it involves the convolution of NJ different
first degree polynomials. Calculating the quotient of Uv (ρv) ÷ µPi,j→ρv , and θv,i,j,1
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and θv,i,j,0 are of time complexity O (NJ). The last three operations of O (NJ) have
to be done for all NJ of the factor nodes for each variable node. Hence the time
complexity of calculating the messages from one variable node to all factor nodes is
of time complexity O ((NJ)2). Repeating this action for all V variable nodes gives
us the time complexity of step 3 of the algorithm to be O ((NJ)2V ).
If we look at equations (3.15) and (3.16), the computation of bv,i,j seems to be of
O
(
NJV 2V
)
time complexity. Since there are NJV of bv,i,j to be computed, step 2
seems to be of O
(
(NJ)2(V )22V
)
time complexity. However some of the computations
are repeated and storing these computations for reuse can reduce the time complexity.
Let κm,i,j =
∏V
l=1 θ
Rl,m
l,i,j,1θ
1−Rl,m
l,i,j,0 . Then µPi,j→ρv(ρv) =
∑2V −1
m=0 Sm,i,jρ
Rv,m
v (1− ρv)1−Rv,m
× κm,i,j
θ
Rv,m
v,i,j,1θ
1−Rv,m
v,i,j,0
. Computation of κm,i,j for all m is of O(V 2
V ) time complexity for
a given factor node Pi,j. Computation of µPi,j→ρv(ρv) for all v is of O(V 2
V ) time
complexity for a given factor node Pi,j. Hence computation of µPi,j→ρv(ρv) from
a single factor node to all variable nodes is of O(V 2V ) time complexity. Hence
total computation for all factor nodes in step 2 comes out to be of O(NJV 2V ) time
complexity.
Hence the complexity of each iteration of the algorithm comes out to beO(NJV (2V +
CNJ)), where C is a constant. This is quadratic with respect to the number of data
points NJ , as opposed to the exponential complexity of the straightforward approach
discussed in the previous sections section.
Once the convergence criteria is met and the algorithm is terminated, the marginal
distribution of ρv is calculated as
P (ρv/O, I) = γ
∏
i,j
µPi,j→ρv(ρv) (3.18)
where γ is a normalization constant which can be calculated to give
∫ 1
0 P (ρv/O, I)dρv = 1.
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3.4 Simulation experiments
We did simulations where the algorithm was tested on synthetic data as well as
applied to real world data. The marginal posterior distributions estimated using
the iterative message passing algorithm were compared with the marginal posteriors
estimated using the time consuming and computationally intensive Markov Chain
Monte Carlo (MCMC) methods and the estimates obtained using both methods
came out to be close thereby verifying the iterative message passing algorithm’s
correctness.
Various literature on MCMC methods exist [12, 13, 16]. We will describe the
details used in our simulations instead of going into a detailed discussion of MCMC
methods. The Markov Chain Monte Carlo Method involves creating a Markov Chain
whose stationary distribution is the required posterior distribution. The Metropolis-
Hastings Algorithm will be used to generate such a Markov Chain since the samples
need to be generated from a non standard probability distribution. This method
will be used to generate samples from the posterior distribution of the unknown
parameters of the vector ρ. These samples can then be used to get an estimate of
the joint as well as the marginal posterior distributions of the unknown parameters
using kernel density estimation.
Samples are drawn from the posterior distribution of ρ using the Metropolis-
Hastings (MH) Algorithm in the following manner. Let the nth sample drawn from
the posterior distribution of ρ be ρ(n) = ( ρ(n)1 ρ
(n)
2 ... ρ
(n)
V ).
1. Initialize all elements of ρ(0) to be 0.5.
2. At the nth iteration of the MH algorithm, generate ρ∗ from the proposal dis-
tribution U(ρ/ρ(n),∆). The proposal distribution and the tuning parameter ∆
will be discussed in the next paragraph.
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3. Calculate the acceptance ratio
D =
P (O/ρ∗, I)U(ρ(n)/ρ∗,∆)
P (O/ρ(n), I)U(ρ∗/ρ(n),∆)
(Recall that the prior of the parameter vector is constant). P (O/ρ∗, I) and
P (O/ρ(n), I) can be easily calculated for known values of ρ∗ and ρ(n) without
the expansion of P (O/ρ, I) described in equation (3.5). Accept ρ∗ as the next
sample ρ(n+1) with probability min(1, D), or keep ρ(n+1) equal to ρ(n) with
probability 1−min(1, D).
4. Repeat steps 2 and 3 to generate samples from the posterior of P (ρ/O, I).
The proposal distribution U(ρ/ρ(n),∆) is such that ρi is Beta distributed with
parameters
ρ
(n)
i
∆
and
1−ρ(n)i
∆
, that is
U(ρ/ρ(n),∆) =
V∏
i=1
ρ
ρ
(n)
i
∆
−1
i (1− ρi)
1−ρ(n)
i
∆
−1
Beta(
ρ
(n)
i
∆
,
1−ρ(n)i
∆
)
(3.19)
where Beta(x, y) is the beta function with parameters x and y and ∆ is a scalar
tuning parameter which controls the variance of the distributions of the ρi’s. It can
be adjusted to give autocorrelation properties of the Markov Chain within acceptable
ranges.
3.4.1 Experiments with synthetic data
To demonstrate the working of the algorithm, we ran simulations of the message
passing algorithm as well as the MH algorithm on synthetic data. We generated
synthetic data from the example described in section II which was derived from the
MAPK signal transduction network, which is a well understood network.
The set of locations where faults can take place was taken to be composed of
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RAF, IRS1, and RHEB. The probabilities of stuck-at-one faults at these locations
(The parameters ρ1, ρ2, and ρ3) were taken as 0.7, 0.4, and 0.2. Synthetic obser-
vations of the observable variable (the variables shown at the bottom of figure 2.1
as arrows) were generated for various drug combinations as inputs (the drugs being
AG1024, AG825, Lapatinib, LY294002, U0126, and Temsirolimus, whose action on
the Boolean network of the MAPK network is shown in figure 2.1) according to the
probability model described in the previous sections. The inputs at the top of the
network corresponding to growth factors (EGF, HBEGF, IGF, and NRG1) were all
taken as 1 (if the cells were being grown on petridishes, then this would be equivalent
to the case where all the four growth factors have been supplied in the serum). Hence
the data set {(oi,1, oi,2, ..., oi,J), Ii} is generated. There are 6 drugs in the Boolean
model. All the 26 − 1 drug combinations were used to generate the data points.
Hence i varies from 1 to 63.
After the synthetic data set was generated, the marginal posterior distributions
of the elements of ρ (The parameters ρ1, ρ2, and ρ3) were estimated using both the
message passing algorithm as well as the MCMC method. For the MCMC method,
the tuning parameter ∆ is set to 0.04 which gives an acceptance rate of 40%. The
reader is referred to [16] for information on acceptance rates. Then the Markov Chain
was run to generate 50,000 samples to attain stationarity (the burn in period). Fol-
lowing this, the Markov chain was run long enough to generate 250,000 samples and
thinned by a factor of 50 (one in 50 samples generated was stored for each param-
eter) resulting in 5000 samples for each ρv. This resulted in effective sample sizes
of atleast 4000 for each of the ρi’s. the reader is referred to [16] for information on
effective sample sizes. The algorithms were implemented in MATLAB. The message
passing algorithm was terminated after 2 iterations which took about 4 seconds. For
our purposes, we used the Hellinger Distance between the marginals of the first pa-
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rameter ρ1 calculated at consecutive iterations of the message passing algorithm to
fall below a certain threshold to signal termination of the algorithm. However other
convergence criterions could also be used. The MCMC samples were generated in
30 minutes after the initial burn in period. The marginal posterior distribution of
ρ1 through ρ3 calculated using both the message passing algorithm and the MCMC
approach are shown in figure 3.3. Kernel density estimation with a Gaussian Kernel
was used to estimate the marginals from the sample values generated using the MH
algorithm. The estimate Pˆ (ρv/O, I) of P (ρv/O, I) is calculated from the samples as
follows
Pˆ (ρv/O, I) =
1
L
L∑
n=1
1√
2piσv
exp
(
−(ρv − ρ
(n)
v )2
2σ2v
)
(3.20)
where σv is the bandwidth of the Gaussian kernel which is set to
δv
L
1
5
. L is the
number of samples generated by the MH algorithm (5000 in our case) and δv is the
standard deviation of the generated samples. This rule of thumb to calculate the
bandwidth of the Gaussian kernel is discussed in [33].
As we can see in figure 3.3, there is almost no difference in the inference of the
marginal posterior distributions of the unknown parameters between the message
passing algorithm and the MCMC approach. The posterior mean of ρv is calcu-
lated from the message passing algorithm as
∫ 1
0
ρvγ
∏
i,j µPi,j→ρv(ρv)dρv and from
the MCMC approach as 1
L
∑
n ρ
(n)
v . These come out to be ( 0.7254 0.3891 0.2799 ) and
( 0.7326 0.3961 0.2830 ) respectively. These estimates are close to each other and to the
actual values of ( 0.7 0.4 0.2 ).
This simulation shows that the message passing algorithm successfully calculates
the posterior marginal distributions of the unknown parameters ρ1 through ρ3 and
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gives the same inferences as the Metropolis-Hastings algorithm. We did simulations
with various values of ρ and for different sets of locations of faults. The iterative
message passing algorithm gave estimates of the posterior marginal distributions of
the parameters same as those estimated using the MCMC approach for all the test
cases considered in our simulations.
3.4.2 Applications to real data
To test our model, we performed experiments on healthy adult fibroblasts where
it is fair to assume that there are no cancer causing mutations present in the tissue.
Hence it is fair to assume that a Boolean regulatory network with no faults would
best model this tissue.
Adult fibroblasts were grown in petri-dishes till confluence and then maintained
in 0.2% FBS (Fetal Bovine Serum) for four days. It is a general assumption that FBS
contains most of the important growth factors. After this, the cells were exposed to
0.2% FBS and 100µM Anisomycin for 30 minutes. Anisomycin is a protein synthesis
inhibitor which activates the MAPK signal transduction network and keeps it respon-
sive to kinase specific inhibitors [2, 10]. That is, with the addition of Anisomycin,
we anticipate the MAPK signal transduction network to respond to the addition of
kinase inhibitors such as U0126. Anisomycin, being a protein synthesis inhibitor,
would also cut off any feedback path which has a translation (protein synthesis) step
in it. The cells were then grouped into three groups (group 0, group 1, and group
2). Group 0 was the control group which was exposed to 100µM Anisomycin only.
Group 1 was exposed to 100µM Anisomycin and 50µM of LY294002. Group 2 was
exposed to 100µM Anisomycin, 50µM of LY294002, and 10µM of U0126. All three
groups were also exposed to 20% FBS along with the other chemicals. LY294002
and U0126 are highly specific inhibitors of PI3 Kinase (PI3K in Figure 2.1) and
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MEK1 respectively. The molecular targets of LY294002 and U0126 are shown in
Figure 2.1. Genes having the SP1 and SRF-ELK response elements in their pro-
moters were quantified through real time PCR and the delta-delta method [22] with
GAPDH as the reference gene and group 0 as the control. The genes were measured
in quadruplets for each experiment.
EGR1 is measured as a reporter gene of SRF-ELK transcription factor [8]. JUN,
and cMYC are measured as reporters of SP1 [31, 20]. Other genes having the SP1
response element in their promoters are Decorin, IRF3 and VEGFA [35, 40, 32, 29].
These six genes were quantified in quadruplets for each experiment. The readings
of each gene are discretized using Otsu’s method [28]. As an example the readings
of ERG1 and their corresponding discretized values are shown in table 3.1. The
threshold level for EGR1 came out to be 0.3824. the expressions above this level
are labeled as 1 and those below are labeled as 0. The measured normalized gene
expression ratios are shown in table 3.2.
For demonstration purposes, we have taken the set of locations where to search
for faults to be composed of ERK1/2 and IRS1 (shown in Figure2.1). The marginal
posterior probability distributions of the probabilities of faults associated with these
two locations are shown in figure 3.4.
As we can see in figure 3.4, the posterior marginal distribution associated with
ERK1/2 comes out to be quite tightly distributed with a mean of 0.1538 while that
for IRS1 comes out to be uniformly distributed between 0 and 1. This is because
the data does not contain any discriminating information about the occurrence of
any fault at IRS1 under this MAPK Boolean model. But it does tell us that the
probability of occurrence of a fault at the variable corresponding to ERK1/2 is pretty
low, judging by its mean to be having a low value of close to 15%. This is expected
since the data comes from adult fibroblasts, where we can be fairly sure that no cancer
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causing mutations are present. If data had been collected after exposure to other
combinations of other drugs (for instance Lapatinib or Temsirolimus) then the data
might have allowed the model to make meaningful inferences regarding occurrences
of faults at locations besides ERK1/2 as well as give sharper confidence intervals
than that shown in figure 3.4.
3.5 Summary and comments on possible future work
In this work we have described a method to estimate the probabilities with which
certain faults have taken place in a given Boolean Regulatory network, provided
we have the observations of the observable variables whose behavior is determined
by the network. We have described the probability model and described a fast
algorithm based on message passing to make the inferences about the posterior
marginal probability distributions of the unknown parameters of the model (These
parameters being the probabilities of the occurrences of the faults). We have com-
pared the performance of the algorithm with Markov Chain Monte Carlo techniques
(the Metropolis-Hastings Algorithm) through simulations, and we have shown that
the message passing algorithm gives results comparable to those obtained using the
MCMC methods with the added advantage of much smaller computation times. We
also applied the model to analyze data collected from fibroblasts, thereby demon-
strating how this model can be used on real world data. Such a computationally
manageable approach has the potential to allow the inference of locations of faults
in a Boolean regulatory network in a probabilistic setting from data, such as gene
expression data. For further information on this work, the reader is referred to [26].
Locating the points of dysregulations in a deterministic Boolean signal trans-
duction network could be used to suggest therapies as described in [18]. Since we
are locating faults in a probabilistic setting, the therapy could be designed keeping
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in mind the tradeoff between treating cancer and managing the side effects of the
treatment. For example, consider a case where we have two possible locations of
faults. Let the computed probability of the occurrence of a fault at the first location
be smaller than that of the second location. Then we may only consider the second
fault in our therapy design process, thereby reducing the exposure of the patient to
excessive drugs which may have unwanted side effects.
Future work could focus on performing experiments on cancerous cell lines being
exposed to various combinations of drugs and infer from the collected data the likely
locations of dysregulations in the corresponding Boolean regulatory network. Also,
algorithms could be developed to automate the process of selecting the set of locations
of faults instead of having the user provide it to the algorithm.
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Figure 3.1: The factor graph representation of a factorizable function. The variable
nodes are circular and the factor nodes are rectangular.
Figure 3.2: The factor graph representation of the probability model of the signal
transduction network. The variable nodes are circular and the factor nodes are
rectangular.
Table 3.1: Gene expression levels and their discrete values for the gene EGR1. The
threshold level using Otsu’s method comes out to be 0.3824 for EGR1.
group 1 normalized gene expression 0.5987 0.7320 0.5586 0.6199
discrete value 1 1 1 1
group 2 normalized gene expression 0.4796 0.2892 0.2535 0.2698
discrete value 1 0 0 0
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Figure 3.3: Marginal posterior distribution of ρ1 through ρ3 calculated using both
the message passing algorithm and the MCMC approach.
Table 3.2: Table showing the normalized gene expression ratios and their reference
sequence (RefSeq) numbers.
EGR1 JUN CMYC DECORIN IRF3 VEGFA
RefSeq NM 001964.2 NM 002228.3 NM 002467.4 NM 133503.2 NM 001571.5 NM 003376.5
Group 1 0.5987 0.4931 0.3209 0.4353 0.5176 0.4444
0.7320 0.6736 0.2852 0.4601 0.4204 0.4989
0.5586 0.6598 0.3439 0.4147 0.3560 0.5176
0.6199 0.7792 0.2994 0.4323 0.3345 0.5105
Group 2 0.4796 0.1550 0.2570 0.2793 0.2624 0.3164
0.2892 0.2793 0.2059 0.3789 0.2553 0.4601
0.2535 0.3015 0.2717 0.3737 0.2253 0.4633
0.2698 0.3415 0.2679 0.3536 0.2031 0.3660
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Figure 3.4: Marginal posterior distribution of the unknown parameters associated
with ERK1/2 and IRS1.
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4. A CONJUGATE EXPONENTIAL MODEL FOR CANCER TISSUE
HETEROGENEITY ∗
4.1 Introduction
In the previous sections we have discussed how the clonal evolution of cells makes
most neoplastic tissues heterogeneous. Hence it becomes important to incorporate
heterogeneity into the modeling of gene regulatory networks which are to be used in
the study of cancerous tissues, especially those oriented towards developing effective
therapies for cancer treatment. An attempt was made in [25] to model cancer tissue
heterogeneity. In that paper, the authors used a collection of Boolean Networks to
model the various subpopulations in a given tissue. A multilevel hierarchical model
was used to model the extent to which each Boolean network affects the behavior
of each of the observed gene expressions. The authors demonstrated the use of this
model by applying it to gene expression measurements from healthy fibroblasts when
they were exposed to various stimuli. Markov Chain Monte Carlo Methods were used
to estimate the posterior probability distributions of the unknown parameters which
would indicate the proportion wise breakup of the tissue under study. In this paper
we make certain approximations to the model which would allow us to employ faster
(variational) methods to carry out the same estimation.
It has been discussed how prior knowledge can be used to model gene regulatory
networks in the form of Boolean networks and how these Boolean networks can
be used to design combination therapies [19, 18]. It has also been discused how an
ensemble of Boolean networks can be used to represent a heterogeneous cancer tissue
∗Parts of this section are reprinted with permission from “A Conjugate Exponential Model for
Cancer Tissue Heterogeneity” by A. K. Mohanty, A. Datta, and V. Venkatraj, 2015. IEEE Journal
of Biomedical and Health Informatics, preprint, c© 2015 IEEE. doi:10.1109/JBHI.2015.2410279.
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in previous sections and also in [25]. In this model, the subpopulations or networks
in the collection of chosen networks exert their effect on the observable variables
(the gene expression ratios) in a weighted average fashion. The objective was to
find these weights associated with each subpopulation or network in the ensemble.
This problem was solved using Markov Chain Monte Carlo (MCMC) methods. In
this paper, we will address this problem of finding out these weights in a variational
Bayes framework resulting in a significant speed-up of the computational time.
Prior knowledge about the qualitative location of faults in the network can be
used to determine the initial model and which networks to choose in the ensemble.
For instance, in 30% of human breast cancers we see an over expression of the ERBB2
gene [37]. This can be interpreted as a stuck-at one fault at the variable corresponding
to ERBB2 in the Boolean network in figure 2.1. Another example is that of pancreatic
cancer where 90% of the cases show a mutated Ras gene [37] translating to a stuck-
at one fault in the corresponding location in the Boolean network. Using such prior
knowledge, it is possible to decide which networks to include in the ensemble.
4.2 Methods
Once the networks to be included in the ensemble have been chosen based on
prior knowledge, the problem is to estimate the weights associated with each of the
networks from collected data. The observable variables can be anything in principle.
We will develop our methods based on normalized gene expression ratios. These are
real valued readings for each gene. [22] discusses the method to measure normal-
ized gene expression ratios using QPCR. When exposed to a certain stimulus (like
a particular combination of kinase inhibitory drugs), some of the output variables,
as shown at the bottom of figure 2.1 using arrows, will be up-regulated or “one” for
some of the Boolean networks in the ensemble, and some of the output variables will
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be down-regulated or “zero” for some of the other networks in the ensemble. For ex-
ample let us consider an example where we have three networks in the ensemble. This
example has also been discussed in [25]. Let the first subpopulation be modeled by a
Boolean network with a stuck-at one fault at ERK1/2, let the second subpopulation
have two stuck-at-one faults at ERBB2/3 and Raf, and let the final subpopulation
have a stuck-at-zero fault at PTEN. The different fault locations corresponding to
the different subpopulations are shown as shaded squares in the single Boolean net-
work in Figure 2.1. Suppose we expose the cell culture to the drug U0126. This is
a kinase inhibitor which targets MEK1 as shown in Figure 2.1. (All the drugs used
in this example are kinase inhibitors whose molecular targets are shown in Figure
1.) Let us also assume that the serum, as typically used in tissue cultures, has EGF,
HBEGF, IGF, and NRG1 in it. Hence in other words, the corresponding variables
represented at the top of figure 2.1 are all one or upregulated. If we observe the
behavior of the transcription factor SP1 (shown at the bottom of the Boolean net-
work in Figure 2.1 with an arrow), the first network has SP1 upregulated while in
the second and third networks, SP1 will be downregulated. If we are observing the
expression for a gene which has the SP1 response element (such as cMYC), then
that gene will be influenced by just the first network to an extent determined by the
weight assigned to that network.
We can represent the activities of the different Boolean networks with relation to
the ith gene (the three Boolean networks with relation to cMYC in the above example)
using a vector di = ( 1 0 0 )
T , where the subscript i stands for the ith gene. We define
this vector as the “expression profile” [25]. This expression profile will depend on
the stimulus given to the tissue (the combination of the kinase inhibitor drugs for
example) and the networks included in the ensemble. These expression profiles will
be provided along with the data. Let the weights associated with the three networks
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with relation to the ith gene be represented by a vector αi = ( αi,1 αi,2 αi,3 )
T . Then
if we are considering a model which combines the networks in a weighted average
fashion, then the gene expression for the ith gene in the overall model could be
quantified by the dot product dTi αi. This approach was used in [25], where the
normalized gene expression ratios were modeled as a ratio of two normal random
variables. This method was an extension of the model described in [7]. Let us say
that several measurements of the ith gene were made. Let di,j be the “expression
profile” for the jth measurement of the ith gene. di,j will depend on the drugs to which
the tissue was exposed. Let ri,j be the corresponding measured gene expression ratio
for the ith gene. Then [25] derived P (ri,j/αi, di,j, c) as
P (ri,j/αi, di,j, c) =
mi,j(ri,j +mi,j)√
2pic(r2i,j +m
2
i,j)
3
2
× exp
(
− 1
2c2
(ri,j −mi,j)2
(r2i,j +m
2
i,j)
)
(4.1)
where mi,j = d
T
i,jαi. The parameter c is the coefficient of variation used to account
for the uncertainty in the data. For a detailed derivation of equation 4.1, the reader
is referred to [25].
Such a distribution has a mode close to around mi,j. Assuming the weights
associated with each network to be the same with relation to all the genes being
observed is a strong assumption. That is, assuming all the αi weight vectors to be
the same would imply that the Boolean networks affect all the genes with exactly the
same ratio. Hence [25] used a multilevel hierarchical model where each of the weight
vectors αi associated with the i
th gene is different from the weight vectors associated
with the other genes, but they all are derived from an underlying distribution which
is an average of all the weight vectors. A schematic diagram of the Bayesian network
of the probability model used in [25] is shown in figure 2.2. The parameter K governs
the topmost level of the model.
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Assuming that there are V different observable variables or genes being measured,
and each gene i has ni observations associated with it (which may come from different
experiments), the variables r1,1 through rV,nV in figure 2.2 indicate the observed gene
expression data. The expression profile associated with each observation indicates
how each network is affecting the output variable. These expression profiles are not
shown in the diagram. The variables α1 through αV indicate the weight vectors
associated with each of the genes being observed. In [25], the authors constrained
all the components of each αi vector to be non-negative and their sum to one. The
logical choice was to make all the αi’s to be sampled from an underlying Dirichlet
distribution with a parameter vector K. The larger the values of the elements of K,
the closer all the αi’s are to each other. Learning this unknown parameter K from
the collected data would indicate the proportion wise breakup of the tissue.
The model parameters were learned in [25] using the Metropolis-Hastings algo-
rithm, which is a Markov Chain Monte Carlo (MCMC) based method. The problem
with such a method is that it is very computationally intensive. There are problems
of convergence, especially since it may be difficult to judge if the Markov Chain has
reached stationarity. In addition, the mixing may be poor which will require us to use
thinning to get a decent effective sample size, which further increases computation
time.
To get around the use of MCMC methods, in this paper we have resorted to the
use of variational methods to estimate the posterior distributions of the unknown
parameters. These methods involve assuming the distribution to have a certain
factorized form and iteratively refining these factors. The variational method can be
conveniently applied to the conjugate exponential family of models [38]. Hence we
approximate the model for heterogeneous cancer tissue presented in [25] in the form
of such a conjugate exponential model and derive the corresponding iterative update
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equations.
4.2.1 A description of the conjugate exponential model for cancer tissue
heterogeneity
Variational methods in Bayesian inference proceed by assuming a certain factor-
ized form of the joint posterior distribution of the unobserved variables [3]. This fac-
torization is done by first partitioning the unobserved variables into disjoint groups.
For example let us say that we have a set of unobserved variables Z and we want to
find an approximation of P (Z/D) which is the posterior distribution of the unob-
served elements conditional on the observed data D. We approximate this by Q (Z),
where
Q (Z) =
M∏
i=1
Qi (Zi) (4.2)
Z1 through ZM are disjointed partitions of the set Z [3]. Then the method proceeds
to minimize the KullbackLeibler (KL) divergence KL (Q(Z)||P (Z/D)). It should be
noted that
lnP (D) = KL (Q(Z)||P (Z/D)) + LQ(D) (4.3)
where
LQ(D) =
∫
ln
(
P (Z,D)
Q(Z)
)
Q(Z)dZ (4.4)
A derivation of equation 4.3 can be found in [3].
As the KL divergence is minimized, the lower bound LQ(D) increases mono-
tonically. This can be used to check if the minimization algorithm has achieved
convergence. Also the maximum achieved lower bound can be used for model selec-
tion.
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The KL divergence is minimized using the following update equation
lnQj (Zj) =
∫
lnP (Z,D)
∏
i 6=j
Qi(Zi)dZi + constant (4.5)
for each j, from 1 through M . The constant term can be adjusted to make sure
that Qj (Zj) is a proper probability distribution, that is it integrates to 1. For a
detailed derivation of the equation 4.5, the reader is referred to [3]. Equation 4.5
shows that the optimum Qj(Zj) depends on the other factors Qi(Zi) for i 6= j. Hence
the equations are solved iteratively by first initializing the parameters which describe
each distribution Qj(Zj) to appropriate values and cycling through the equations and
replacing the old values with the corresponding updates. The variational method can
be applied in a straightforward manner to the class of conjugate exponential models.
Conjugate exponential models are those where the conditional distributions involved
in the model belong to the exponential family and are conjugate with respect to the
parent variables [38]. Therefore we modeled heterogeneous cancerous tissue in the
form of a conjugate exponential model which would allow us to use the variational
framework to estimate the proportion wise breakup of the tissue under study.
As discussed previously, each collected gene expression reading has an “expression
profile” associated with it which depends on the Boolean Networks included in the
ensemble and the stimulus provided to the tissue in the form of kinase inhibitory drug
combinations. Each observed variable or gene i has a weight vector αi associated with
it. The weight vectors, which determine the extent to which each chosen Boolean
network in the ensemble affects the ith observable gene, are different for all the genes
whose expressions are measured. Hence here too we will use a Hierarchical model
(which, in addition will also belong to the conjugate exponential family).
The Bayesian network of the model is shown in figure 4.1. Since we are concerned
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with the ratio with which the different networks affect the observed gene expressions,
we can reduce redundancy by constraining the elements of each weight vector αi to
sum to 1, as was done in [25]. That is
N∑
q=1
αi,q = 1 (4.6)
where N is the number of networks in the ensemble. Therefore we have αi,N =
1−∑N−1i=1 αi,q. For convenience, we are not constraining the elements of the weight
vectors to be non negative. As we will see from simulations and from applications
to real data, the posterior distributions of these elements will have very little prob-
abilities in the regions where any element is negative. The probability distribution
of any gene expression reading is defined to be normally distributed with a mean of
dTi,jαi and a precision of ρ (inverse of variance). We are considering all the measured
gene expression ratios to have the same precision, although it is possible to have
a hierarchical structure for the precision too. From equation 4.6, we have dTi,jαi =∑N−1
q=1 αi,q(di,j,q−di,j,N)+di,j,N , where di,j,q’s are the elements of the expression profile
di,j. Define µi,j = di,j,N , Di,j = (di,j,1− di,j,N , di,j,2− di,j,N , ..., di,j,N−1− di,j,N)T , and
βi = (αi,1, αi,2, ..., αi,N−1)T . Then we have
P (ri,j/βi, ρ, di,j) = N
(
ri,j|DTi,jβi + µi,j, ρ−1
)
(4.7)
The probability distribution of βi is defined to be normally distributed with a mean of
K and a precision matrix of Λ, whereK = (K1 K2 ... KN−1 ) and Λ is an (N−1)×(N−1)
positive definite matrix. Hence we have
P (βi/K,Λ) = N (βi|K,Λ−1) (4.8)
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Hence the unknown parameters are ρ, K, and Λ, which in the Bayesian framework
are simply unobserved variables (along with all the βi’s). K could be interpreted
as the weights associated with the first N − 1 networks. 1 −∑N−1q=1 Kq could be
interpreted as the weight associated with the N th network.
The Bayesian approach needs us to define certain priors over the unknown pa-
rameters. Thus we define the prior over ρ to be a gamma distribution with a shape
and inverse scale parameter to be ao and bo respectively. The prior over K and Λ
was taken as the Normal-Wishart distribution. Thus we have
P (ρ) = Gamma (ρ|ao, bo) (4.9)
P (K/Λ) = N (K|Ko, (qoΛ)−1) (4.10)
and
P (Λ) = Wish
(
Λ|no,Λ−1o
)
(4.11)
The joint posterior distribution of the unknown variables is
P (ρ, β,K,Λ/r) ∝ P (Λ)P (K/Λ)P (ρ)×
V∏
i=1
([
ni∏
j=1
P (ri,j/βi, ρ, di,j)
]
P (βi/K,Λ)
)
(4.12)
where β is the set of all the βi’s and r is the set of all the observed data. Our model
belongs to the conjugate exponential family. In the following section, we will approx-
imate the joint posterior distribution of the unknown variables using the variational
approach. This would in turn simplify the derivation of the marginal distributions
of the variables of interest (such as K which would indicate the proportion wise
breakup of the tissue).
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4.2.2 Derivation of the variational update equations
The approximation Q (ρ, β,K,Λ) of the posterior P (ρ, β,K,Λ/r) is assumed to
factorize in the following form.
Q (ρ, β,K,Λ) = Qρ(ρ)Qβ(β)QK,Λ(K,Λ) (4.13)
We then use equation 4.5 to derive the update equations for each of the factors. First
we apply equation 4.5 to Qρ(ρ). As per equation 4.5, we have
lnQρ(ρ) = E6=ρ [lnP (ρ, β,K,Λ/r)] + constants (4.14)
where
E 6=ρ [lnP (ρ, β,K,Λ/r)] =∫
[lnP (ρ, β,K,Λ/r)]Qβ(β)QK,Λ(K,Λ)dβdKdΛ (4.15)
The terms which are not dependent on ρ can be absorbed into the constants. Thus
we get
lnQρ(ρ) = E6=ρ
[
lnP (ρ) +
V∑
i=1
ni∑
j=1
lnP (ri,j/βi, ρ, di,j)
]
+ constants (4.16)
Upon simplifying we get
lnQρ(ρ) = aρ ln(ρ)− bρρ+ constants (4.17)
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where
aρ = ao +
1
2
V∑
i=1
ni (4.18)
and
bρ = bo +
1
2
V∑
i=1
ni∑
j=1
{(ri,j − µi,j)2 − 2(ri,j − µi,j)DTi,jE[βi]
+DTi,j(E[βiβ
T
i ])Di,j} (4.19)
and constants are all those terms which do not depend on ρ. Looking at the form
of equation 4.19 we can deduce Qρ(ρ) to be gamma distributed with aρ as the shape
parameter and bρ to be the inverse scale parameter. That is
Qρ(ρ) = Gamma (ρ|aρ, bρ) (4.20)
E[βi] and E[βiβ
T
i ] depend on Qβ(β).
Using similar steps, we get the result Qβ(β) =
∏V
i=1Qβi(βi). This factorization
is not implicitly assumed, but comes as a result of applying equation 4.5 to derive
the update equations for Qβ(β). Upon inspection, Qβi(βi) comes out to be normally
distributed as follows
Qβi(βi) = N (βi|µβi ,Λ−1βi ) (4.21)
where Λβi is a (N − 1) × (N − 1) positive semidefinite precision matrix and µβi is
the mean vector of length N − 1 which are defined as
Λβi = E[Λ] + E[ρ]
ni∑
j=1
Di,jD
T
i,j (4.22)
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and
µβi = Λ
−1
βi
{E[ΛK] + E[ρ]
ni∑
j=1
Di,j(ri,j − µi,j)} (4.23)
All the expectations in equations 4.22 and 4.23 are done with respect toQρ(ρ)QK,Λ(K,Λ).
Following similar steps, QK,Λ(K,Λ) comes out to be factorizable asQK,Λ(K/Λ)QK,Λ(Λ)
which are defined as follows:
QK,Λ(K/Λ) = N
(
K|KoK , [(qo + V )Λ]−1
)
(4.24)
QK,Λ(Λ) = Wish
(
Λ|no + V,Λ−1oΛ
)
(4.25)
where KoK and Λ
−1
oΛ are defined as:
KoK =
∑V
i=1 E[βi] + qoKo
V + qo
(4.26)
Λ−1oΛ = Λ
−1
o +
V∑
i=1
E[βiβ
T
i ] + qoKoK
T
o − (qo + V )KoKKToK (4.27)
KoK and ΛoΛ are of length N − 1 and of dimension (N − 1)× (N − 1) respectively.
Now that the optimal form of each factor in the approximation is known, the
expectations can be easily computed. Thus we get:
E[βi] = µβi (4.28)
E[βiβ
T
i ] = µβiµ
T
βi
+ Λ−1βi (4.29)
E[Λ] = (no + V )ΛoΛ (4.30)
E[ρ] =
aρ
bρ
(4.31)
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E[K] = KoK (4.32)
E[ΛK] = (no + V )ΛoΛKoK (4.33)
The constants aρ, bρ, Λβi , µβi , KoK , ΛoΛ are all initialized to appropriate values and
then iteratively updated by cycling through the update equations 4.18, 4.19, 4.22,
4.23, 4.26, and 4.27 using the values of the expectations shown in equations 4.28
through 4.33. Equation 4.4 is used to calculate the lower bound at each iteration.
In the interest of space, the exact equation of the lower bound is not shown here.
However in our simulations and applications to real world data, we will show how
convergence is judged using the lower bound.
4.2.3 Simulation experiments
To demonstrate the algorithm, we ran simulations on synthetic data. First, the
synthetic data was generated from the following example. Three different Boolean
networks with stuck-at faults were taken in the ensemble. The first network was
chosen to have a stuck-at one fault at Ras. The second network was chosen to have
a stuck-at zero fault at PTEN. The third network was chosen to have a stuck-at one
fault at RAF. Hence N = 3. The three locations are shown as shaded squares in a
single Boolean network in figure 2.1. The activity of the four transcription factors
shown at the bottom of figure 2.1 would be different in the three networks for any
given drug combination. A total of 63 different drug combinations were chosen as
the stimulus. The location of the targets of these kinase inhibitory drugs is shown
in figure 2.1. Since there are six different drugs, there would be 63 different possible
combinations excluding the case of no drug exposure. It was assumed that five genes
per transcription factor were measured, hence a total of twenty different observable
variables were assumed in the simulation. Hence V = 20. Each experiment was
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repeated ten times in the simulation. This would result in each observable being
observed 10 times. Hence ni = 10 for all i’s ranging from 1 through 20. Since the
number of networks is three, hence the length of the vector K is two. K was set to
be ( 0.1 0.3 ). Hence the first network has a weight of 0.1 associated with it, the second
network has a weight of 0.3 associated with it, and the third network has a weight
of 0.6 associated with it. ρ was set to be 100 and Λ was set to be
Λ = [ 0.01 0.0050.005 0.008 ]
−1
.
For the purposes of demonstration, the parameters for the prior distributions of
the parameters were chosen as follows. ao and bo for the prior over ρ were both
chosen to be 0.5. This would make the prior over ρ to have a mean of 1. Ko was
chosen to be ( 1/3 1/3 )T and qo was chosen to be 0.001. Hence the prior belief assigns
equal weights to all the three networks. The small value of qo means that the prior
is spread out and non informative. As for the prior over Λ, no was chosen to be 1.1
and Λo was chosen as
Λo = [ 0.01 0.0050.005 0.008 ]
−1
.
For comparison purposes, we also did the posterior inference using Gibbs sam-
pling and found point estimates of the unknown parameters using Expectation Max-
imization algorithm. The full conditionals of the unobserved variables in the Gibbs
sampling algorithm are listed below. (Some of the notations used here are similar
to those used in the derivation of the variational update equations. The reader is
advised to keep in mind that the full conditionals are derived independent of the
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derivations in the previous subsection).
The full conditional of Λ is:
P (Λ/...) = Wish
(
Λ|nΛ,Λ−1Λ
)
(4.34)
where
nΛ = no + V + 1 (4.35)
Λ−1Λ = Λ
−1
o + qo(K −Ko)(K −Ko)T +
V∑
i=1
(βi −K)(βi −K)T (4.36)
The full conditional of K is:
P (K/...) = N
(
K|qoKo +
∑V
i=1 βi
qo + V
, (qo + V )Λ
)
(4.37)
The full conditional of ρ is:
P (ρ/...) = Gamma (ρ|aρ, bρ) (4.38)
where
aρ = ao +
1
2
V∑
i=1
ni (4.39)
and
bρ = bo +
1
2
V∑
i=1
ni∑
j=1
{(ri,j − µi,j −DTi,jβi)2
(ri,j − µi,j)2 − 2(ri,j − µi,j)DTi,jβi + (DTi,jβi)2} (4.40)
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The full conditionals of each of the βi’s are:
P (βi/...) = N
(
βi|µβi ,Λ−1βi
)
(4.41)
where
Λβi = Λ + ρ
ni∑
j=1
Di,jD
T
i,j (4.42)
and
µβi = Λ
−1
βi
(
ΛK + ρ
ni∑
j=1
(ri,j − µi,j)Di,j
)
(4.43)
The expectation maximization algorithm can also be used to find a maximum
likelihood estimate of the unknown parameters ρ, K, and Λ. The hidden variables
which are not observed are simply all the βi’s for i ranging from 1 through V .
The derivation is skipped in the interest of space. The Expectation Maximization
Update equations are as follows. Define ρ(n), K(n), and Λ(n) to be the estimates of
the parameters in the nth iteration. Define Σ
(n)
i , M
(n)
i and S
(n)
i to be
Σ
(n)
i =
[
Λ(n) + ρ(n)
ni∑
j=1
Di,jD
T
i,j
]−1
(4.44)
M
(n)
i = Σ
(n)
i
[
Λ(n)K(n) + ρ(n)
ni∑
j=1
Di,j(ri,j − µi,j)
]
(4.45)
S
(n)
i =
ni∑
j=1
{(ri,j − µi,j)2 − 2(ri,j − µi,j)DTi,jM (n)i
+DTi,j(M
(n)
i M
(n)T
i + Σ
(n)
i )Di,j} (4.46)
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Then the update equations are:
ρ(n+1) =
∑V
i=1 ni∑V
i=1 S
(n)
i
(4.47)
K(n+1) =
∑V
i=1M
(n)
i
V
(4.48)
{
Λ(n+1)
}−1
=
1
V
V∑
i=1
(
M
(n)
i M
(n)T
i + Σ
(n)
i
)
−K(n+1)K(n+1)T (4.49)
where ρ(n+1), K(n+1), and Λ(n+1) are the updated values of the parameters.
Figure 4.2 shows the posterior marginal distributions of the elements of K de-
rived using both the Gibbs sampling method as well as the variational Bayesian
method. The third graph in figure 4.2 is simply the marginal posterior density of
1−K1−K2. As we can see, the distributions computed using both the methods are
almost identical. Same is true for the posterior distribution of ρ which is shown in
figure 4.3. Figure 4.4 shows how the lower bound stops improving after 80 iterations
of the variational algorithm thereby indicating convergence. The mean of the poste-
rior distribution of K comes out to be (0.1044, 0.3015)T and (0.1042, 0.3011)T from
the variational method and the Gibbs sampling method respectively. The maximum
likelihood estimate of K using the expectation maximization algorithm comes out
to be (0.1042, 0.3015)T . Figure 4.5 shows that the log likelihood function shows no
significant improvement after 100 iterations of the expectation maximization algo-
rithm, thereby indicating convergence. All three estimates are close to the actual
value of (0.1, 0.3)T thereby showing the correctness of the algorithms.
From figure 4.2, we can see that the marginal posterior distributions of the ele-
ments of K lie mostly within the interval (0, 1). The marginal posterior distribution
of 1−∑Nq=1 Kq (the third graph in figure 4.2) also lies within the interval (0, 1).
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4.2.4 Verification using experimental data
In order to test the model, we need to collect data from a tissue where the
dominant population or the dominant network is already known. In a cancerous cell
line, one cannot be sure which network is dominant. But in a normal cell line, such
as adult fibroblasts, it is fair to assume that a network modeling a faultless MAPK
signal transduction network would be the most dominant one, no matter what other
networks are included in the ensemble. Hence we performed a simple experiment on
adult fibroblasts to demonstrate the approach. For a detailed description of the wet
lab procedures, the authors are referred to [25]. The experiments were performed
on three groups of cell cultures. The first group was not exposed to any kinase
inhibitory drugs and served as the control. The second and third groups were exposed
to the drugs LY294002 and a combination of LY294002 and U0126 respectively.
Their target locations are shown in figure 2.1. GAPDH (Glyceraldehyde-3-Phosphate
Dehydrogenase) was used as the reference gene. Genes having the SP1 or the SRF-
ELK response elements in their promoters were quantified through real time PCR
and the delta-delta method [22]. A total of ten different genes (including alternative
transcripts) were quantified [25]. Hence V = 10. Their measured expression values
are shown in table 4.1.
For the sake of demonstration we assumed 3 networks to be in the ensemble.
Hence N = 3. Network 1 has no mutations, i.e. no stuck-at faults. This net-
work models the normally behaving fibroblasts. Network 2 is assumed to have a
stuck-at one fault at ERK1/2 and network 3 is assumed to have stuck-at one faults
at SRF-ELK1 and SRF-ELK4. The “expression profiles” for all the genes for the
experimental conditions of the second and third groups are known (can be easily
derived from figure 2.1) and depend on the behavior of the 3 networks included in
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the ensemble. These are shown in table 4.1.
The marginal posterior distributions of the elements of K are computed using the
variational approach and are shown in figure 4.6. The lower bound stops improving
after 300 iterations as can be seen in figure 4.8, thereby indicating convergence. Only
the results of the variational computations are shown since the Markov Chain Monte
Carlo approach could not produce decent effective sample sizes. As we can see, most
of the probability mass lies in the valid region. Specifically, most of the posterior
marginal probabilities associated with the elements ofK are within 0 and 1. Hence we
get meaningful interpretations of the inferred value of K. The mean of the posterior
distribution of K comes out to be ( 0.6716 0.2740 )T . As expected, the first faultless
network representing normal fibroblasts has the maximum influence on the behavior
of the observables, close to 67%. The other two networks have influences of 27%
and 6% respectively. [25] reports values of ( 0.6453 0.2255 0.1292 )T which are very close
to those calculated in this paper. The Expectation maximization algorithm also
gives very close values of ( 0.6764 0.2745 0.0490 )T . The log likelihood stops improving
after 250 iterations of the Expectation Maximization algorithm as can be seen in
figure 4.9, thereby indicating convergence. This simple experiment shows how this
model can be used to determine the proportional breakup of the subpopulations in
a heterogeneous tissue.
4.3 Summary and comments on possible future work
Here the problem of heterogeneity in cancer tissue cell populations was addressed
and a model was developed which uses a collection of different Boolean networks to
model the various sub populations in the tissue. It was demonstrated using both syn-
thetic and real world data collected from fibroblasts, how this model can be used to
find out the relative abundance of the various subpopulations in a given tissue under
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study using QPCR gene expression data. This work is an extension of the previous
work in [25]. The novelty of this work is in the improvement in the computation time.
A hierarchical conjugate exponential model was used in this paper, which allowed
the use of variational methods for Bayesian estimation of the relative abundances
of the various subpopulations. The efficacy of the variational methods was verified
by comparing the results obtained to those obtained using MCMC (Gibbs sampling)
and Maximum likelihood (Expectation Maximization) methods. Determining the
relative abundance of the various subpopulations in an individual patient could be
used to come up with customized combination therapies which are tailored to the
patient so as to improve the efficacy and reduce side effects (for example, we may
want to target the dominant subpopulation(s) using the minimal amount of drugs
so as to reduce side effects).
Variational methods are becoming increasingly important as Bayesian methods
are gaining interest since these methods allow for speedy computation of posterior
distributions of variables of interest. Moreover the lower bound, which is easily com-
puted in variational methods, provides for an effective proxy for the likelihood of the
data which can be used for model selection. Hence this approach can also be extended
to solving the problem of determining how many Boolean networks to include in the
ensemble as well as determining which Boolean networks to include in the ensemble.
Besides variational methods, other methods, such as expectation propagation may
also be used to solve the problem of determining the dominant subpopulations in
a heterogeneous cancer tissue in a Bayesian framework with reduced computational
requirements.
The model in this paper was developed keeping QPCR gene expression data in
mind. However similar methods can be developed which use data from more state
of the art technologies such as Next Generation Sequencing and flow cytometry.
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Figure 4.1: A Bayesian network representing the conditional dependencies in the
conjugate exponential model.
Figure 4.2: Posterior marginal distributions of the elements of K for synthetic data.
76
Figure 4.3: Posterior marginal distribution of ρ for synthetic data.
Figure 4.4: Increase of the log of the lower bound with iterations of the variational
Bayes algorithm for synthetic data.
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Figure 4.5: Increase of data log likelihood with the iterations of the expectation
maximization algorithm for synthetic data.
Table 4.1: Table showing the gene expression measurements, their “expression pro-
files”, and their reference sequence (RefSeq) numbers.
gene RefSeq group 1 group 2
expression profile gene expression expression profile gene expression
EGR1 NM 001964.2 1 1 1
0.5987
0 1 1
0.4796
0.7320 0.2892
0.5586 0.2535
0.6199 0.2698
JUN NM 002228.3 1 1 1
0.4931
0 1 0
0.1550
0.6736 0.2793
0.6598 0.3015
0.7792 0.3415
BIRC5 NM 001168.2 1 1 1 0.5799 0 1 0 0.3842
CMYC NM 002467.4 1 1 1
0.3209
0 1 0
0.2570
0.2852 0.2059
0.3439 0.2717
0.2994 0.2679
Decorin
NM 133504.2
1 1 1
0.0819
0 1 0
0.0087
NM 133505.2 0.0728 0.0242
NM 133507.2 0.3345 0.1661
NM 133503.2
0.4353 0.2793
0.4601 0.3789
0.4147 0.3737
0.4323 0.3536
IRF3 NM 001571.5 1 1 1
0.5176
0 1 0
0.2624
0.4204 0.2553
0.3560 0.2253
0.3345 0.2031
VEGFA NM 003376.5 1 1 1
0.4444
0 1 0
0.3164
0.4989 0.4623
0.5176 0.4633
0.5105 0.3660
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Figure 4.6: Posterior marginal distributions of the elements of K for data collected
from fibroblasts.
Figure 4.7: Posterior marginal distribution of ρ for data collected from fibroblasts.
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Figure 4.8: Increase of the log of the lower bound with iterations of the variational
Bayes algorithm for data collected from fibroblasts.
Figure 4.9: Increase of data log likelihood with the iterations of the expectation
maximization algorithm for data collected from fibroblasts.
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5. CONCLUSIONS ∗
In this dissertation, we have presented methods to model cancer tissues primar-
ily by using Bayesian methods. These methods range from accurate modeling and
inference using MCMC methods to computationally efficient methods such as belief
propagation and variational Bayesian methods. The thesis was divided into three
sections, each focusing on a certain sub-problem. A summary of these three sections
is provided in the following paragraphs.
In section 2, we addressed the important problem of heterogeneity in cancer
tissues and presented a model which has the ability to use prior pathway knowledge
and knowledge about likely mutations in cancers to represent a heterogeneous cancer
tissue as an ensemble of faulty Boolean networks. We demonstrated the general idea
of our approach by considering the observed variables to be genes transcribed by key
transcription factors. We also demonstrated how the Metropolis-Hastings MCMC
method can be used to estimate the relative effect that each subpopulation exerts on
the observed variables. This estimate gives us an idea about which subpopulation
is the most dominant one among all the subpopulations in the ensemble. Such
estimates, if obtained using data from individual patients, could help customize
combination therapy design and could help improve the success rate of such cancer
therapies. for more information on this work, the reader is referred to [25].
∗Parts of this section are reprinted with permission from “A Model for Cancer Tissue Heterogene-
ity” by A. K. Mohanty, A. Datta, and V. Venkatraj, 2013. IEEE Transactions on Biomedical
Engineering, volume 61, no. 3, pages 966 - 974, c© 2013 IEEE. doi:10.1109/TBME.2013.2294469,
and “Using the message passing algorithm on discrete data to detect faults in boolean regu-
latory networks” by A. K. Mohanty, A. Datta, and V. Venkatraj, 2014. BMC Algorithms for
Molecular Biology, volume 9, no. 20, 12 pages. doi:10.1186/s13015-014-0020-6, and “A Conju-
gate Exponential Model for Cancer Tissue Heterogeneity” by A. K. Mohanty, A. Datta, and V.
Venkatraj, 2015. IEEE Journal of Biomedical and Health Informatics, preprint, c© 2015 IEEE.
doi:10.1109/JBHI.2015.2410279.
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In section 2, the methods suggested depended heavily on MCMC techniques.
However for these methods to become practically applicable, the computational com-
plexity needs to be reduced. Various computationally efficient methods exist to speed
up the computation of posterior distributions. In section 3, an algorithm based on
loopy belief propagation or message passing has been presented to estimate the most
likely locations of faults in a Boolean network based on observed data. We have com-
pared the performance of the algorithm with Markov Chain Monte Carlo techniques
(the Metropolis-Hastings Algorithm) through simulations, and we have shown that
the message passing algorithm gives results comparable to those obtained using the
MCMC methods with the added advantage of much smaller computation times. We
also applied the model to analyze data collected from fibroblasts, thereby demon-
strating how this model can be used on real world data. Such a computationally
manageable approach has the potential to allow the inference of locations of faults
in a Boolean regulatory network in a probabilistic setting from data, such as gene
expression data. For further information on this work, the reader is referred to [26].
In section 4, an approximation of model described in section 2 is presented so as
to allow for the use of variational Bayesian methods in the estimation of conditional
posterior distributions of the unobserved variables in the model. The novelty of this
work is in the improvement in the computation time. A hierarchical conjugate expo-
nential model was used in this section, which allowed the use of variational methods
for Bayesian estimation of the relative abundances of the various subpopulations.
The efficacy of the variational methods was verified by comparing the results ob-
tained to those obtained using MCMC (Gibbs sampling) and Maximum likelihood
(Expectation Maximization) methods. Variational methods are becoming increas-
ingly important as Bayesian methods are gaining interest since these methods allow
for speedy computation of posterior distributions of variables of interest. Moreover
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the lower bound, which is easily computed in variational methods, provides for an
effective proxy for the likelihood of the data which can be used for model selection.
Hence this approach can also be extended to solving the problem of determining
how many Boolean networks to include in the ensemble as well as determining which
Boolean networks to include in the ensemble. Besides variational methods, other
methods, such as expectation propagation may also be used to solve the problem
of determining the dominant subpopulations in a heterogeneous cancer tissue in a
Bayesian framework with reduced computational requirements. This could be a pos-
sible direction for future research.
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